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Miranda, José Guadalupe (Ph.D., Biochemistry) 
Elucidating Zinc Distribution In Cancerous Prostate Cells Using Novel FRET Sensors 
 
Thesis directed by Associate Professor Amy E. Palmer, Ph.D. 
 
Zinc (Zn2+) is an important trace element that is found throughout the human body and 
plays essential roles in proteins to ensure structural integrity and catalytic activity.  It is 
the second most abundant transition metal in the body.  Transition metals are required 
for numerous enzymes, proteins, and cellular processes.  It is important for cells to 
regulate distribution of metals because numerous enzymes and cellular processes 
depend on transition metals, yet metal imbalance leads to a wide range of diseases.  
Prostate tissue has the highest Zn2+ concentration in the body compared to other 
tissues but Zn2+ is significantly depleted upon onset of malignancy.  Numerous studies 
have revealed that cancerous prostate tissue exhibits dramatically reduced levels of 
Zn2+ and that the levels of Zn2+ appear to correlate with progression from benign to 
invasive and metastatic cancer.  The mechanistic correlation between malignancy and 
Zn2+ levels is not well understood and in particular, it is not clear whether Zn2+ depletion 
contributes to or is a consequence of disease progression.  Although the majority of 
Zn2+ found in cells in bound by proteins, enzymes, and cellular ligands, pools of free 
Zn2+ have been identified in pancreatic islet cells, brain, and prostate.  In this current 
study we used normal and cancerous prostate cells as a model system to map free Zn2+ 
levels in the nucleus, cytosol, endoplasmic reticulum, and mitochondria to identify the 
differences in Zn2+ at the subcellular level.  This was accomplished by using novel Zn2+ 
sensors based on fluorescence resonance energy transfer (FRET) targeted to each 
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organelle compartment and carrying out live cell imaging experiments.  FRET sensors 
are powerful tools to monitor Zn2+ dynamics in cells.  This type of probes gives us the 
ability to monitor Zn2+ in multiple cellular compartments or simultaneously track two 
cellular signals using orthogonal FRET sensors.  Such studies allow us to precisely 
correlate the timing of two interdependent cellular events or to track the movement of 
ions or molecules from one compartment to another.  We discovered that the free Zn2+ 
pool in the nucleus and cytosol is higher in our prostate cancer cell line models 
compared to normal cell line.  In the ER we observed that the free Zn2+ level in normal 
prostate cells is about 4 times higher than all three prostate cancer cell lines models 
used.  Similar results were observed in mitochondria, revealing 3-4 times higher Zn2+ in 
the normal cells compared to all three prostate cancer cell lines.  Although all three 
prostate cancer cell lines used in this study were characterized by over 50% reduction 
in total cellular Zn2+, surprisingly we discovered this reduction did not translate into 
across-the-board deficiency in intracellular Zn2+ stores, but rather there was substantial 
redistribution of Zn2+ between subcellular locations.  In an effort to define how and why 
Zn2+ pools are redistributed in prostate cancer, we measured the changes in expression 
levels of key Zn2+ regulatory proteins such as transporters (hZIP1, hZIP2, hZIP3, ZnT1, 
ZnT2, ZnT4, and ZnT7).  Our results suggest that there is a dysregulation of the Zn2+ 
transporters in cancerous prostate cells and there is some heterogeneity between the 
prostate carcinoma cell lines.  To complement existing tools, we developed a suite of 
sensors using alternately colored FRET pairs using tSapphire/TagRFP, tSapphire/mKO, 
Clover/mRuby2, mOrange2/mCherry, and mOrange2/mKATE that were used 
simultaneously with CFP-YFP sensors.  Using these combinations of FRET sensors we 
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were able to monitor Zn2+ uptake simultaneously in two compartments, revealing that 
nuclear Zn2+ rises quickly, whereas the ER, Golgi, and mitochondria all sequester Zn2+ 
more slowly and with a delay of 600-700 sec.  These new green-red sensors provided 
the starting point for developing vesicle-targeted sensors.  In summary, this thesis 
details efforts to develop new fluorescent sensors for defining free Zn2+ in cells and 
applies these sensors to quantify free Zn2+ in normal prostate and cancerous cells at the 
subcellular level.  We discovered unprecedented redistribution of Zn2+ stores in all three 
cancer cell lines and discovered this correlates, at least in part, to alteration of Zn2+ 
transporters.  This work not only provides the first quantitative maps of Zn2+ distribution 
in cells, it also provides a critical glimpse of how Zn2+ is altered with disease 
progression. 
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1.1 Zinc Homeostasis 
 In biological organisms, Zinc (Zn2+) is the second most abundant transition metal and is 
critical to proteins, transcription factors, immune function, and neurotransmission (1-3).  Zn2+ 
deficiency claims many lives per year worldwide (5) underscoring the importance of 
understanding how organisms take up and distribute Zn2+ within the cell.  Zn2+ is an essential 
cofactor for numerous proteins and enzymes such as acetylcholinesterase (6), alcohol 
dehydrogenase, DNA and RNA polymerases, Nerve Growth Factor (NGF) (7), and finally 
transcription factors such as Zif268 (8) and MTF-1 (9).  About half of all transcription factors in 
the human genome contain Zn2+ finger motifs and hence require this metal to function (10).  
This shows the importance of Zn2+ at the genome wide level and how it is essential for gene 
production.  For example, nuclear receptors, such as retinoic acid, vitamin D, thyroid hormone, 
glucocorticoids, and estrogen, are all Zn2+ finger proteins (11, 12).  In neurogenesis, cellular 
proliferation, and brain development the receptors mentioned are important gene regulators 
(12). 
Mammalian cells contain high levels of Zn2+ (~ 0.1 - 0.5 mM) (13, 14), but the majority is 
bound to enzymes, proteins, and other low molecular weight species.  Excess Zn2+ is buffered 
by cellular ligands because too much Zn2+ within the cell is toxic (15).  The primary protein 
responsible for Zn2+ buffering is metallothionein (MT), which is itself regulated by Zn2+ (16, 17).  
The free (i.e. unbound) Zn2+ concentration has been estimated to be in the pM to nM range (18, 
19) , but there is general agreement based on more recent estimates that free Zn2+ in the 
cytosol ranges from ~ 100pM – 400 pM in many different cell types (18, 19).  There is far less 
information about the level of free Zn2+ in organelles.  Recent studies from our group have used 
newly developed probes to measure free Zn2+ in organelles in HeLa cells, resulting in estimates 
of free Zn2+ pools in the endoplasmic reticulum (0.9 pM), Golgi apparatus (0.6 pM), and 
mitochondria (0.14 pM) (18, 20).  Although resting levels of free Zn2+ in the cytosol are low, 
recent studies demonstrate that Zn2+ can be released from MT by a variety of cellular signals 
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(21, 22), indicating that Zn2+ levels may be highly variable.  For example, the Zn2+ finger 
transcription factor Egr-1 signals MT to release Zn2+ (23) and metal transcription factor-1 (MTF-
1) is activated by the release of Zn2+ from MT (24).  Because Zn2+ can be mobilized, it strongly 
suggests that the levels of Zn2+ are dynamic and this mobilized Zn2+ may be transported 
between different organelles particularly given the large number of Zn2+ transporters on 
organelles.  Figure 1.1 is schematic summary of how much Zn2+ is within the cell and how it is 
distributed. 
 Zn2+ is regulated a number of ways within cells via transporters that are localized both in 
the membrane and organelles.  These transporters are known to move Zn2+ from outside of the 
cell into the cytoplasm as well as store it in different compartments.  The two types of Zn2+ 
transporters are the Zrt-, Irt-like Proteins (ZIP) and Cation Diffusion Facilitators (CDP) also 
referred to as ZnTs (25).  The ZIP family Zn2+ transporters move Zn2+ from the extracellular 
space into the cytosol and from inside organelles to the cytosol (26).  On the other hand, the 
ZnT family transporters move Zn2+ from the cytosol to the extracellular space as well as from the 
cytosol into organelles (27).  To date there have been 10 ZnTs and 14 ZIP transporters 
identified.  Table 1.1 and Table 1.2 represent a complete list of these Zn2+ importers and 
exporters as well as their tissue specificity.  In addition to these transporters, two other proteins 
are known to be fundamental regulators of Zn2+ homeostasis, metallothionein (the cellular buffer 
mentioned above) and the transcription factor MTF-1, which regulates both metallothionein and 
ZnT1 levels in response to Zn2+ (9, 17). 
1.2 Zinc and Prostate cancer 
 Among all the tissues in the body, the prostate has the highest levels of Zn2+ per gram of 
tissue (28, 29).  When normal prostate cells become malignant they lose over 50% of total  
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Figure 1.1.  Schematic representation of cellular Zn2+. 
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Table 1.1 Cation Diffusion Facilitator (ZnT) Physiological Expression 
Zn2+ Transporter Tissue (Localization) Ref 
ZnT1 Ubiquitous (Plasma membrane, vesicles) (15) 
ZnT2 Small Intestine, kidney, mammary glands (vesicles, secretory vesicles) (30) 
ZnT3 Neurons (vesicles) (31) 
ZnT4 Small Intestine, vesicles (vesicles, endosomes) (32) 
ZnT5 Small Intestine, secretory vesicles (secretory granules) (33) 
ZnT6 Small Intestine (TGN) (33) 
ZnT7 Lung, Small Intestine (Golgi apparatus, vesicles) (34) 
ZnT8 Pancreas (secretory vesicles) (25) 
ZnT9 Lung (35) 
ZnT10 Homologous to ZnT1 (no known tissue of localization) (36) 
 
 
 
 
 
 
Table 1.2 Zrt-, Irt-like Protein (ZIP) Physiological Expression 
Zn2+ Transporter Tissue (Localization) Ref 
hZIP1 Ubiquitous (plasma membrane) (37) 
hZIP2 Liver, ovary (38) 
hZIP3 Blood Cells (31) 
hZIP4 Small Intestine, Colon (apical, plasma membrane) (39) 
hZIP5 Liver, kidney, pancreas (39) 
hZIP6 Lung, breast (plasma membrane) (40) 
hZIP7 Ubiquitous (Golgi apparatus) (40, 41) 
hZIP8 Kidney, liver, testis, brain, small intestine (42) 
hZIP9 No known function Unknown 
hZIP10 Liver, Brain, Erythroid Progenitor Cells (plasma membrane) (43) 
hZIP11 Member of gufA subfamily of ZIP transporters (25) 
hZIP12 Brain (25) 
hZIP13 Golgi apparatus  (44) 
hZIP14 Liver, kidney, testis (45) 
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cellular Zn2+ (46, 47).  The depletion of Zn2+ in prostate cancer cells has been shown to be an 
important factor in the development and progression of metastasis of prostate cancer (46).  The 
primary region of the prostate that undergoes metastasis is the peripheral zone and cancers 
derived from this zone are known to be more invasive than transition zone cancers (48).  The 
peripheral zone is also the region that contains the highest levels of Zn2+ (49).  The majority of 
the studies done to date have shown that there is marked depletion of Zn2+ in the prostate upon 
onset of malignancy, observed in cell lines, tissue samples, and mouse studies.  In cells the 
most common cell lines used have been LNCaP, DU-145, and PC-3 prostate cancer cell lines 
and each study has shown that prostate cancer cell lines are depleted of Zn2+ (46, 50-53).  In 
tissue samples from human patients with benign prostate hyperplasia (BPH) and prostate 
cancer, the levels of Zn2+ are also depleted (54-58).  Tissue studies to determine Zn2+ content 
were elucidated by atomic absorption spectroscopy, electrothermal atomizeratomic absorption 
spectrometry (ETA-AAS), or Inductively coupled plasma mass spectrometry (ICP-MS).  
Moreover, studies have demonstrated that mice with prostate cancer lose a large percentage of 
total Zn2+ as well (59-62).  In mice, similar to human cells or tissue samples, the low Zn2+ levels 
have been correlated with the downregulation of Zn2+ transporters such as hZIP1 (59).  
Additionally, in a transgenic adenocarcinoma of the prostate mouse models a ZnT7 null-
mutation leads to low levels of Zn2+ and is associated with aggressive development of prostate 
cancer (62).  These studies demonstrate that Zn2+ is markedly decreased whether the scientific 
group chooses to study cells, tissue, or mice.  To date it is still not clear why cancer cells have 
lower Zn2+ content than normal cells, nor is it established from what areas of the cell Zn2+ is 
missing.  Therefore, it is important to define why and from what regions of the cell Zn2+ is 
reduced as a first step in elucidating the consequence of depletion.   
There is some evidence for changes in expression levels of Zn2+ transporters in cell lines 
and tumor samples, but many reports are incomplete.  For example, numerous studies examine 
mRNA but not protein levels, or focus one specific transporter instead of a suite of transporters. 
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Additionally, there are inconsistencies in the literature, i.e. the reports directly disagree with one 
another (32, 47, 52, 53).  The expression of Zn2+ transporters studies in prostate samples that 
have been carried out to date is presented in Table 1.3. 
1.3 Prostate Cancer Cell Line Models 
 The focus of this thesis is to characterize the Zn2+ distribution in cancerous and 
noncancerous prostate cell lines.  Prostate cancer is a complex and heterogeneous disease 
characterized by a wide diversity of molecular markers.  Table 1.4 summarizes a number of 
prostate cancer cell lines as well as tissue origin. For our current studies we chose two newly 
established prostate cancer cell lines; Dura matter Cancer of the Prostate (DuCaP) and 
Vertebral column Cancer of the Prostate (VCaP) cells that were immortalized by Pienta and 
colleagues (63, 64).  DuCaP and VCaP prostate cancer cell lines were chosen because they 
exhibit molecular diversity not currently represented in the commonly used cell lines (65, 66).  In 
addition to these features, these prostate cancer cell lines were karyotyped to contain many 
abnormalities characteristic of metastatic prostate cancer (65, 66).  In addition, we used Lymph 
Node Cancer of the Prostate (LNCaP) cells (67), a well-established cell line.  LNCaP is 
characterized by androgen responsiveness, expression of a mutated form of androgen receptor 
(AR) and wild type p53.  Finally, to compare our results we used RWPE1, a standard 
noncancerous prostate cell line (68).  From the large repertoire of prostate cancer cell lines we 
chose the above cell lines because of their key characteristics.  Other cell line models such as 
the widely used DU-145 and PC-3 cells do not express the androgen receptor, produce PSA, or 
are sensitive to hormones (69, 70). 
1.4 Genetically Encoded FRET Sensors to Monitor Zinc 
 Genetically encoded sensors are broadly defined as sensors that are encoded by a 
sequence of DNA that is genetically incorporated into cells and subsequently translated into 
functional sensor protein in live organisms.  Our laboratory has created a family of genetically  
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Table 1.3.  mRNA and Protein Expression of Specific Zn2+ transporters in prostate cancer 
cell lines and tissue samples 
Transporter Detection Method Origin Result Reference 
hZIP1 RT-PCR LNCaP & PC3 
Cells (Human) 
• Upregulated with prolactin 
• Down-regulated when exposed 
to Zn2+ 
(71) 
hZIP1 & hZIP2 RT-PCR & Western PC3 and LNCaP • Transfected pCMV & pCMV-
hZIP1; down-regulation of hZIP1 
in pCMV only (empty vector) 
transfected cells at the mRNA 
and protein level; over-
expressing cells with pCMV-
hZIP1 show more Zn2+ uptake 
(PC3 only) 
• RT-PCR show a down-regulation 
of mRNA in PC-3 compared to 
LNCaP 
• Sense and anti-sense 
oligonucleotides were used to 
partially knock-down hZIP1 and 
anti-sense decrease the 
expression of hZIP1 and Zn2+ 
uptake as measured by 65Zn; 
(RT-PCR & Western) 
• hZIP2 undetectable 
(72) 
ZnT1 RT-PCR & Western PC3 and LNCaP • ZnT1 expression levels 
increased after zinc and 
cadmium in PC3 but not LNCaP 
(Western & RNA) 
• RNA levels significantly 
decreased in prostate cells 
compared to Benign Prostate 
Hyperplasia (BPH) by semi-
qPCR 
(73) 
ZnT4 Immunofluorescence 
& Western 
Mouse Fibroblast 
Cells, NIH3T3 
Cells (mouse), 
LNCaP, & PC3 
• ZnT4 detected in transfected 
MFC, NIH3T3, and PC3 with 
ZnT4-HA 
• Whole Cell Lysate and surface 
biotinylated ZnT4-HA detected in 
MFC & 3T3 cells by western 
• ZnT4 protein found in LNCaP not 
PC3 cells (Western) 
(32) 
hZIP1, hZIP2, 
ZnT1, ZnT3, 
ZnT4 
RT-PCR LNCaP • LNCaP cells were deprived of 
Zinc called AIDL 
• ZnT1 and ZnT3 down-regulated 
in LNCaP vs. AIDL cells 
• ZnT4 upregulated in LNCaP vs. 
AIDL cells 
• No significant change in hZIP1 
and hZIP3 in both cell lines 
(53) 
hZIP1 RT-PCR and  
Immunofluorescence 
LNCaP & PC3 • mRNA decreased in prostate 
cancer cells compared to BPH 
• PC3 & LNCaP show similar 
distribution of hZIP1 
(52) 
hZIP1 & hZIP2 RT-PCR Rat—ventral, 
lateral, and dorsal 
• Down regulation on all three 
anatomical sections of the 
prostate for hZIP1 
• hZIP2 not detected in ventral or 
dorsal prostate ONLY in lateral; 
down-regulated 
(74) 
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hZIP2 & hZIP3 Immunofluorescence Human tissue 
samples 
• both down-regulated in 
adenocarcinoma glands 
• function in the re-uptake and 
conservation of zinc from 
prostatic fluid 
• hZIP1 functions in the 
accumulation of zinc from 
circulation 
(55) 
ALL ZnT’s and 
hZIPs 
qRT-PCR RWPE-1, LNCaP, 
PC3, & DU-145 
• Detected mostly all in all cell 
lines, EXCEPT ZnT3, ZnT10, 
hZIP2, hZIP4, & hZIP5 
• NO significant difference in 
mRNA levels between cell lines 
for ZnT2 & ZnT5-7 between all 
cell lines 
• ZnT1 and hZIP10 levels were 
elevated in RWPE1 
• ZnT4 elevated in LNCaP 
compared to other cell lines 
• hZIP1 elevated in DU-145 
compared to other cell lines 
• Exposure to Zn2+ had no effect 
on the mRNA levels of all cell 
lines EXCEPT; increased ZnT1-2 
in RWPE1 and decreased ZnT7, 
hZIP7 and hZIP10 
• ZnT1 levels increased in PC3 
cells but to a lower magnitude 
that of RWPE1 
(50) 
ZnT1 – ZnT7 Immunohistochemistry Mouse Tissue • ZnTs were differentially 
expressed in prostate during 
sexual maturation 
• ZnT1 detected on lateral 
membrane 
• ZnT2/ZnT5  detected  in the ER 
• ZnT3 not detected 
• ZnT4 detected in luminal border 
• ZnT6/7 across lobes of all ages 
(75) 
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Table 1.4 List of Prostate Cancer Cells 
Cell Line Site of Origin Reference 
DuCaP Dura matter (64) 
VCaP Spinal cord (63) 
DU-145 Brain (76, 77) 
PC-3 Bone (78) 
LNCaP Lymph Node (67) 
ARCaP Ascites (79) 
NCI-H660 Lymph Node (80, 81) 
ALVA-101 Bone (82) 
ALVA-55 Lymph Node (83) 
LAPC-4 Lymph Node (84) 
MDA PCa 2a Ascites (85) 
MDA PCa 2b Bone (85) 
CTPE Lung (86) 
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encoded sensors which contain a Zn2+ binding domain with a donor cyan fluorescent protein 
(CFP) and acceptor yellow fluorescent protein (Citrine or circular permuted Venus) with 
apparent disassociation constants (Kd') that range from pM to µM (18, 20, 87).  These sensors 
undergo a conformational change upon binding Zn2+ resulting in an increase in fluorescence 
energy transfer (FRET) from the donor to the acceptor.  Figure 1.2 depicts the changes in the 
emission spectrum of one sensor as the concentration of Zn2+ is increased.  Figure 1.3 shows 
representative Zn2+ binding curves of some of the FRET sensors created and characterized in 
our laboratory.  These sensors have been expressed in mammalian cells and have been 
targeted to the cytosol, nucleus, mitochondria, ER, and Golgi and have proven to be an effective 
and powerful tool in monitoring Zn2+ homeostasis in HeLa and neuronal cells (18, 20, 87). 
 Although genetically encoded FRET sensors are powerful tools to monitor ions such as 
Zn2+ or Ca2+, it is imperative that the sensor does not alter or perturb the cellular environment 
(88).  This is important because the majority of Zn2+ binding domains that we use in FRET 
sensors are naturally occurring domains such as the Zif268 transcription factor (8, 87).  It was 
previously shown that analogous Ca2+ sensors (cameleons) which are based on the ubiquitous 
calmodulin protein were perturbed in some cellular environments (89, 90).  Redesign of the 
calmodulin within the sensor so that it could not bind endogenous effectors led to improved 
responses, suggesting that sensors have the potential to interact with other cellular constituents 
(91). 
 In our laboratory, Dr. Yan Qin, has performed extensive studies that demonstrate that, to 
the best of our detection, our sensors are not perturbing the cellular environment.  Figure 1.4a 
shows that the level of measured Zn2+ does not depend on the sensor concentration, suggesting 
that at the concentrations present in these experiments, the incorporation of sensor into cells 
does not alter the resting Zn2+ levels.  On the other hand, small molecule fluorescent Zn2+ 
sensors, such as FluoZin3-AM were observed to be highly perturbing to the cellular environment 
at high concentrations as depicted in Figure 1.4b.   
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Figure 1.2.  In vitro Fluorescence Spectra of a Ratiometric FRET Sensor.  
 Representation of a FRET sensor changes in the emission spectra upon increasing 
 [Zn2+].  Arrows indicate a decrease in the donor fluorescence and an increase in the 
 acceptor emission. 
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Figure 1.3 In vitro Zn2+ titration of FRET sensors.  Data (symbols) are represented as 
 the percent saturation of each sensor as a function of Zn2+ concentration.  Each data 
 trace is fit to binding model (solid line) in order to determine the Kd’.  Blue trace 
 represents ZapCY1 (Kd' - 2.5 pM), red trace ZapCY2  (Kd' - 811 pM), green trace ZifCY1  
 (Kd' - 1 µM), and black trace ZifCY2 (Kd' - 150 µM)  (18, 87). 
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Figure 1.4.  Percent saturation of a FRET sensor and FluoZin3-AM as a function of 
 the sensor concentration.  The percent saturation of either ZapCY2 or FluoZin3-AM 
 was calculated at rest by obtaining Resting Ratio (R), RTPEN, and RZn.  These ratios are 
 then converted into a percent using the following equation: % = (R - RTPEN)/(RZn - RTPEN).  
 A) The percent saturation of the sensor at rest as a function of sensor concentration, 
 each point in the graph represents a region of interest in a single cell.  B) The percent 
 saturation of the small molecule dye at rest as a function of dye concentration.  Estimate 
 of free Zn2+ is more reliable with a genetically encoded sensor versus FluoZin3-AM 
 because for the dye the estimated free Zn2+ is dependent of sensor concentration.  
 Graphs are courtesy of Dr. Yan Qin. 
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In addition to genetically encoded sensors, there are a large number of small molecule 
sensors for Zn2+.  Great strides have been made over the years to increase the repertoire of 
small molecule fluorescent indicators for Zn2+.  Table 1.5 lists the main small molecule 
indicators developed to date.  There are many differences between small molecule and 
genetically encoded sensors and each class of indicators has notable strengths and 
weaknesses.  One of the primary strengths of small molecule sensors is that they tend to have 
larger dynamic ranges than genetically encoded sensors (i.e. the change in signal upon Zn2+ 
binding is greater than for genetically encoded sensors).  One of the primary reasons for this is 
that the vast majority of small molecule sensors are "intensiometric”, i.e. Zn2+ binding induces a 
change in fluorescence intensity and intensiometric sensors can typically achieve higher 
dynamic ranges than “ratiometric” sensors, where Zn2+ binding induces a shift in the excitation 
or emission spectrum.  High dynamic range intensiometric sensors are valuable for measuring 
Zn2+ dynamics, particularly when the change in Zn2+ levels might be small.  However, these 
sensors pose problems for precise quantification of Zn2+, because the intensity depends not 
only on Zn2+ but also the concentration of sensor (as discussed above) and the pathlength (i.e. 
cell thickness).  In addition, small molecule sensors lack the capacity to be explicitly targeted to 
organelles, whereas genetically encoded sensors can be targeted to different compartments of 
the cell by attaching a signal sequence.   Small molecule dyes are extruded from the cell after a 
couple of hours (92).  On the other hand, genetically encoded sensors can easily be 
incorporated into cells and imaged over long periods of time (days to weeks).  Lastly, the 
concentration of a genetically encoded sensor can be controlled if it is placed under an inducible 
promoter such as Tet-promoter in which the ligand can be titrated to induce sensor production.  
Because the goal of this thesis is to define Zn2+ levels in different cellular locations, I focused on 
the development and use of genetically encoded sensors. 
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Table 1.5 Small molecule fluorescent Zn2+ sensors 
Sensor Name Structure Kd' 
(nM) 
Ratiometric References 
Zinpyr (ZP) 
ZP1 
ZP2 
ZP3 
ZP4 
ZP5 
ZP6 
ZP7 
  
0.7 
0.5 
0.7 
0.9 
1.1 
0.9 
0.8 
 
 
No 
No 
No 
No 
No 
No 
No 
(93) 
FluoZin-3 
 
15 No (94) 
Zinbo-5  2.2 Yes (95) 
 
Zinspy-5 
 
Low 
µM 
No (96, 97) 
Quinozin 
 
30,000 
µM 
No (98) 
IndoZin 
 
3,000 
µM 
Yes (99) 
Zin-naphthopyr-1 
 
0.55 No (99) 
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1.5 Significance 
 It is important for cells to regulate the distribution of metals because numerous enzymes 
and cellular processes depend on transition metals, yet metal imbalance leads to a wide range 
of diseases.  Our current knowledge of metal homeostasis is limited because we are barely 
scratching the surface of metal distribution in living cells.  Homeostasis is generally defined as 
the ability of a cell to regulate internal conditions through feedback controls to maintain stability 
independent of the outside conditions.  Understanding metal homeostasis involves establishing 
where metals are located and tracking the movement of metals from one compartment to 
another.  For example, Inositol 1,4,5-trisphosphate (IP3) receptor signaling causes a 
redistribution of Ca2+ stores from the ER to the cytosol and perturbations of this pathway may 
play a role in Huntington's and Alzheimer's disease (100).  Therefore, in order to understand 
how metals move throughout the cell it is important to acquire the necessary tools to monitor 
these dynamics, and identify the proteins that regulate these actions. 
 Zn2+ is an important transition metal and is required in many processes of the cell from 
cell cycle regulation (101), gene regulation (102), and cell death (103).  In addition, Zn2+ 
deficiency has been known to impair the immune system by lowering the number of T-cells 
(104).  In pancreatic islet cells (105), brain (2, 29), and prostate (28), Zn2+ dysregulation has 
been linked to human disease.  In the pancreas an upregulation of hZIP4 at the membrane 
increases the Zn2+ concentration contributing to tumor progression (106). 
 Although there is no mechanistic information on how Zn2+ perturbations contribute to 
prostate cancer, study after study done in prostate cancer cells and tissues demonstrate low 
levels of Zn2+ compared to normal prostate.  Among all the tissues in the body, the prostate has 
the highest levels of Zn2+ per gram of tissue (28, 29).  Moreover, when normal prostate cells 
become malignant they lose over 50% of total cellular Zn2+ (46, 47).  According to the American 
Cancer Society, prostate cancer claims the lives of approximately 30,000 men a year in the 
United States (http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-
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key-statistics and (107))  In addition to the high number of lives claimed per year due to prostate 
cancer, it is estimated that 1 out 6 men will be diagnosed with this disease during his lifetime 
(108).  A significant problem with this disease is the lack of appropriate biomarkers for different 
stages of cancer progression.  Understanding Zn2+ dysregulation in prostate cells is important 
for establishing the role of Zn2+ in disease progression. 
 Given the importance of Zn2+, it is surprising how few robust quantitative tools we have 
to look at this important ion in cell.  As explained earlier in this chapter, small molecule 
fluorescent dyes lack the capacity to localize to organelles and consequently are unable to 
identify and track critical pools of Zn2+.  Genetically encoded FRET sensors have the capacity 
and potential to fill this gap, as these sensors enable us to track Zn2+ using fluorescence 
microscopy techniques over long periods of time whereas small molecules are removed from 
the cell in a matter of hours.  While we have made great strides in moving this field forward, we 
are stuck in one place in the sense that we are able to monitor Zn2+ in one compartment at a 
time in a single cell.  To date most FRET sensors made, either to monitor Zn2+, Ca2+, or monitor 
protein-protein interactions have utilized the CFP-YFP FRET pair (109).  In order to observe 
Zn2+ dynamics, orthogonal sensors need to be generated to be used alongside CFP-YFP to 
dissect Zn2+ movement in cells.  Therefore one of the primary focuses of this thesis was to 
develop FRET sensors using alternate fluorescent proteins in the hopes that such sensors could 
be used alongside CFP-YFP sensors to track metal movements in cells. 
1.6 Conclusion 
 Zn2+ is the second most abundant transition metal in the body and the highest 
concentrations of Zn2+ in the body are found in the prostate gland.  The goal of this study has 
been to reveal the differences in Zn2+ distribution at the subcellular level in noncancerous 
compared to cancerous cells.  Our study was focused on using novel tools (genetically encoded 
FRET sensors) to monitor Zn2+ distribution in cells (Chapter 2) and to correlate this with 
changes in expression levels of mRNA and proteins that regulate Zn2+ homeostasis (Chapter 
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3).  By demonstrating which compartments have Zn2+ pools, we can further understand the 
fundamental role of Zn2+ in the cell and be able to define how Zn2+ is dysregulated in prostate 
cancer cells.  The changes that occur in proteins that regulate Zn2+ homeostasis will provide a 
complete picture of how and why Zn2+ is altered in cancerous prostate cells.  This is an 
important first step in defining the role of Zn2+ dysregulation in tumor progression. 
 The generation of new alternate colored Zn2+ sensors (Chapter 4) will represent a 
marked advance in our ability to monitor Zn2+ dynamics, will have more versatile optical 
properties, and will be pH insensitive.  Because these new sensors will be pH insensitive, they 
will be instrumental in developing tools to monitor metal homeostasis in places like vesicles 
were the pH is low.  This would be a major advance as there is currently no reliable way to 
measure vesicular Zn2+.  Very little is known about the concentrations of metal within acidic 
places and these new sensors will open up areas of research that may elucidate the signal 
mechanisms of metal storage.  Preliminary work (Chapter 5) suggests that FRET sensors can 
indeed be targeted to vesicular pools and are sensitive to Zn2+ perturbations in these locations. 
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2.1 Abstract 
 Prostate tissue is characterized by high levels of Zn2+ compared to other soft tissues in 
the human body.  Upon malignant transformation, the prostate gland loses over 50% of its total 
Zn2+.  The mechanism of Zn2+ depletion has not been defined, nor is it established from which 
compartment of the cell Zn2+ is lost.  While Zn2+ is an important transition metal necessary for 
many cellular functions, it has not been determined whether this reduction in Zn2+ is a cause or 
consequence of the malignancy.  In this study we use Inductively Coupled Plasma Mass 
Spectrometry (ICP-MS) to quantify total cellular Zn2+, X-Ray Fluorescence Microscopy (XRFM) 
to examine the distribution of total Zn2+, and genetically encoded fluorescence resonance 
energy transfer (FRET)-based Zn2+ sensors with specific localization sequences to map out free 
Zn2+ levels in the nucleus, cytosol, endoplasmic reticulum, and mitochondria.  These techniques 
enabled us to compare the Zn2+ levels between a normal prostate and three prostate cancer cell 
lines to define the changes in Zn2+ between normal and malignant cells.  Using XRFM and 
FRET sensors we identified a massive redistribution of Zn2+ from the normal to the cancerous 
prostate cell lines. 
2.2 Introduction 
 The prostate consists of the dorsal, lateral, and ventral lobes (1).  The peripheral zone of 
the prostate is known to contain the highest levels of Zn2+, and this is also the zone that 
contributes to the majority of malignancies (2).  It is also been postulated that another function 
of Zn2+ in prostate is its role in inhibiting m-aconitase in the Krebs Cycle, preventing the 
oxidation of citrate to aconitase which causes citrate to accumulate before it is secreted, and 
influences the bioenergetics of cells (2). 
 Zinc is the second most abundant transition metal in the human body and is critical for 
proteins, transcription factors, immune function, and neurotransmission (3-5).  Although the 
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majority of Zn2+ found in cells is bound by proteins, enzymes, and cellular ligands, pools of free 
Zn2+ have been indentified in pancreatic islet cells (6), brain (4), and prostate (7).  Numerous 
studies have revealed that cancerous prostate tissue exhibits dramatically reduced levels of 
Zn2+ and that the levels of Zn2+ appear to correlate with progression from benign to invasive and 
metastatic cancer (8-11).  The mechanistic correlation between malignancy and Zn2+ levels is 
not well understood and in particular, it is not clear whether Zn2+ depletion contributes to or is a 
consequence of disease progression. 
 To date there have been no studies that define the subcellular distribution of Zn2+ in 
prostate cancer cells that would allow us to determine whether Zn2+ is missing from a particular 
compartment or whether prostate cancer is characterized by a systematic depletion of Zn2+ 
throughout the cell.  In this study we set out to elucidate differences in Zn2+ levels and 
distribution between two newly established prostate cancer cell lines and compare them to a 
normal prostate cell line and a widely-used traditional cancer cell line model.   
Like all cancers, prostate cancer is a complex and heterogeneous disease characterized 
by a wide diversity in molecular markers, thus complicating efforts to identify an appropriate in 
vitro model system.  We chose to characterize two newly established prostate cancer cell lines: 
dura matter cancer of the prostate (DuCaP) and vertebral cancer of the prostate (VCaP), which 
derive from metastases to distinct locations within the same patient (12, 13) because they 
exhibit molecular diversity not currently represented in the commonly used cell lines (14, 15).  
Both cell lines express normal androgen receptor (AR), mutant p53, are androgen sensitive, 
produce large quantities of prostate specific antigen (PSA), and are tumorigenic in mice without 
the need to coinject with stroma (12, 13).  Spectral karyotyping of these cell lines revealed a 
large number of complex chromosomal abnormalities, consistent with their derivation from late-
state tumors (14).  In contrast, the traditional prostate cancer cell line model that has been used 
for the past 30 years, lymph node cancer of the prostate (LNCaP) (16), is characterized by 
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androgen responsiveness, expression of a mutated form of AR and wild type p53. However 
LNCaP cells are not tumorigenic in mice unless coinjected with stroma.  To compare differences 
between cancerous and normal we used RWPE1 normal prostate cell line (17).  
 Using a combination of techniques that measure total Zn2+ and free Zn2+ levels, we 
identified systematic differences in Zn2+ homeostasis in all three cancer cell lines compared to 
the normal cell line.  In particular, we discovered that while total Zn2+ is substantially depleted in 
prostate cancer cells, at the subcellular level, there is a redistribution of free Zn2+ among the 
various compartments of the cell, such that in some locations free Zn2+ is actually elevated in 
the cancer cells.  This study will open up new areas of research to get closer to the question of 
why Zn2+ is markedly depleted by studying specific compartments and proteins that channel this 
metal in and out of them.  
2.3 Experimental Methods 
Cell Culture.  RWPE1 (normal prostate cell line), VCaP (prostate cancer cell line), and LNCaP 
(prostate cancer cell line) were obtained from the American Type Cell Collection (ATCC).  
DuCaP was a kind gift from Dr. Scott M. Lucia at the University of Colorado Anschutz Medical 
Campus (Denver, CO).  RWPE1 cells were cultured in Keratynocyte-Serum Free Media (KSFM) 
supplemented with 0.05 mg/mL bovine pituitary extract, 5 ng/mL epithelial growth factor (Life 
Sciences), 100 U/mL penicillin and 100 µg/mL streptomycin.  DuCaP, VCaP, and LNCaP cell 
lines were cultured in Roswell Park Memorial Institute (RPMI) media (Life Sciences) 
supplemented with 10% (v/v) fetal bovine serum (Atlanta Biologicals), L-glutamine, 100 U/mL 
penicillin, and 100 µg/mL streptomycin.  All cell lines were incubated at 37ºC with 5% CO2, 
changing the media every 2-3 days. 
Inductively Coupled Plasma Mass Spectrometry.  RWPE1, DuCaP, VCaP, and LNCaP cell 
lines were grown to 80-90% confluency in their respective media.  Cells were collected by 
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adding 4 mL of trypsin to cells and incubating them at 37°C with 5% CO2 for 5 minutes.  After 
the incubation period, 8 mL of media were added to quench the trypsin activity and dislodge 
cells from plate.  Cells were placed onto 15 mL conical tubes and centrifuged for 5 minutes at 
1200 rpm.  The centrifugation step was followed by aspiration of the media out of tube and 
resuspension in 3-6 mL of media.  20 µL of cells were removed and placed in a 1.5 mL tube.  
Cells were counted using Trypan Blue (Life Technologies) in a hemocytometer.  Approximately 
400,000 cells were placed into 15 mL metal-free conical tubes (Life Sciences Products), spun 
down at 5000 rpm for 2 minutes, and the supernatant was removed.  To each tube 200 µL of 
low grade nitric acid (Fisher Scientific) was added followed by 3 minutes of continuous 
vortexing.  Following the vortex period, tubes were placed in ice for 2 hours, and subsequently 5 
mL of Chelex-100 (Sigma Aldrich) treated water was added.  Tubes were mixed well and 300 µL 
of each sample was removed to perform a bicinchoninic acid (BCA) assay to quantify the 
protein concentration for each sample.  Samples were taken to The Laboratory for 
Environmental and Geological Studies (LEGS) ICP-MS facility for analysis. 
X-Ray Fluorescence Microscopy.  XRFM studies were performed in collaboration with Dr. 
Samuel Webb at the Stanford Linear Accelerator Center (SLAC, Palo Alto, CA).  Cells were 
grown in 12-well plates with 100 mesh gold plated formvars (Electron Microscopy Sciences) 
until cells were close to 100% confluency.  Cell coated formvars were then plunged into liquid 
ethane for approximately 10 seconds followed by storage in a cryogrid with liquid nitrogen.  
During the time period when formvars with cells were in liquid nitrogen, cyrovials were prepared 
in liquid nitrogen with 1 mL of 2% anhydrous EM Grade glutaraldehyde diluted in acetone 
(Electron Microscopy Sciences) and stored at -70°C in liquid nitrogen for 48 hours.  After 48 
hour incubation, glutaraldehyde was removed from cryovials and formvars were washed with 1 
mL of acetone followed by an incubation period of acetone. 
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 To dry samples, the pressure chamber of a Critical Point Drying (CPD) apparatus was 
frozen down to 0°C using short bursts of CO2(g).  After the chamber reached 0°C it was filled to 
its midpoint with acetone and the element specimen holder with formvars was placed in there.  
Once formvars were in the chamber, exhaust of CPD was closed and CO2(g) was turned on for 
about 3 minutes followed by opening the exhaust, this step was done 3x.  This was followed by 
heating the pressure chamber to 42°C for 5 minutes.  After the 5 minute incubation period the 
exhaust was opened slightly until it reached 200 psi and then the exhaust was fully opened.  
Samples were taken from the specimen holder and placed in a grid box which was then sealed 
in a jar with desiccant until samples were taken to the linear accelerator.  Schematic of x-ray 
beam and sample is presented in Figure 2.1.   
 Before taking samples to the linear accelerator we used our Zeiss Axiovert 200M 
microscope to map out bright field images of the formvars to enable overlay of the x-ray 
fluorescence image with bright field ones.  The XRFM Zn2+-map was collected using the x-ray 
source on Beam Line 2-3 at the Stanford Synchrotron Radiation Laboratory.  The x-ray energy 
was tuned to 14.2 keV to detect Zn2+ and focused on the sample using Kirkpatrick-Baez mirrors.  
The sample was scanned in the beam using a step size of 1 µm x 1 µm.  Zinc was quantified 
using a strip of high resolution Zinc Telluride (ZT). 
Fractionation of Nucleus and Cytosol for ICP-MS.  Cells were grown to approximately 90% 
confluency.  Media was removed and cells were briefly washed in 2 mL cold phosphate buffered 
saline (PBS) pH 7.4 and scrapped off the plate in 2 mL PBS pH 7.4 and placed in ice chilled 2 
mL eppendorf tubes.  Cells were centrifuged for 5 minutes at 3000 rpm at 4°C, discarding the 
supernatant.  The cell pellet was resuspended in Buffer 1 (0.33M sucrose, 10 mM HEPES pH 
7.4, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP-40, protease inhibitor cocktail) and incubated in ice for 
30 minutes with occasional pipeting using P200 tips.  After ice incubation, tubes were 
centrifuged at 3000 rpm for 5 minutes at 4°C, and the supernatant (Cytosolic Fraction) was  
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Figure 2.1. X-Ray Fluorescence Microscopy (XRFM) for Measuring Total Zn2+.  A) A high 
energy x-ray beam is tuned to the K-edge shell of Zn2+ ejecting a core electron and resulting in 
emission of a photon of light when an electron from the L-edge shell relaxes to the K-edge.  B) 
Schematic diagram representing how XRFM uses an x-ray source that is focused to a spot on a 
macroscopic sample.  The sample can be moved within the beam resulting in scanning of the 
beam across the sample to generate a map or image.   
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collected without disturbing the pellet.  The pellet was resuspended in 300 µL of Buffer 1 and 
placed in ice for 20 minutes, centrifuged at 3000 rpm for 5 minutes at 4°C, discarding the 
supernatant leaving the pellet as dry as possible.  The pellet was resuspended in 300 µL of 
Buffer 2 (0.45 M NaCl, 10 mM HEPES pH 7.4, 1.5 mM MgCl2, 0.2 mM EDTA pH 8.0, 25% 
glycerol) and incubated in ice for 1 hour.  After incubation tubes were centrifuged at 14,000 rpm 
for 20 minutes at 4°C, collecting the supernatant (Nuclear Fraction). 
 For ICP-MS preparation details please refer to above section entitled Inductively 
Coupled Plasma Mass Spectrometry. 
FRET-based Zn2+ Sensors.  A schematic representation of the type of FRET sensor used in 
this study is depicted in Figure 2.2.  Table 2.1 represents the dual Zn2+-finger amino acid 
sequence of Zap1 and Zap2.    All FRET sensors used to define the free Zn2+ concentrations in 
the cytosol, ER, Golgi, and mitochondria are described in Dittmer et al., Qin et al., and Park et 
al., (18-20).  Nuclear localization was accomplished by fusion of the signal sequence 
(PKKKRKVEDA) to the carboxy terminal end of the ZapCY2 sensor. 
Cell Culture and Microscopy.  RWPE1, DuCaP, VCaP, and LNCaP cell lines were seeded 
onto 3.5 cm glass bottom imaging dishes with their respective media and incubated at 37°C with 
5% CO2 until cells were 40-50% confluent.  1 µg of sensor cDNA was transiently transfected 
using TransIT®-LT1 (Mirus) as specified by manufacturer instructions. 
 Forty-eight hours after transfection, cells were imaged using phosphate, calcium, and 
magnesium free HEPES-buffered Hanks' balanced salt solution (HHBSS) media (5.36 mM KCl, 
137 mM NaCl, 16.65 mM D-Glucose, and 30 mM HEPES) pH 7.4.  This buffer is made in our 
laboratory because phosphates are known to precipitate Zn2+.  Buffer was generated with 
Chelex-100-treated water (Sigma Aldrich).  Cell imaging was performed on a Zeiss Axiovert 200 
M microscope with a Cascade 512B CCD camera (Roper Scientific) and xenon arc lamp  
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Figure 2.2. Schematic Diagram of a FRET Sensor.  The sensor is composed a Cyan 
Fluorescent Protein (CFP) and the citrine variant of the Yellow Fluorescent Protein (YFP).  The 
Zn2+ binding domain is relatively unstructured in the absence of Zn2+ and undergoes a 
conformational change upon Zn2+ binding leading to an increase in FRET from the donor CFP to 
the acceptor YFP.   
 
 
 
 
 
 
 
 
FRET 
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                          Table 2.1.  Amino acid sequence of Zap Zinc Binding Domains (ZBD) in the  
     ZapCY1 and ZapCY2 sensors 
 
 
 
(XBO75) using MetaFluor software (Universal Imaging) to operate the system.  CFP (430/24 
excitation, 455 dichroic, 470/24 emission), YFP (495/10 excitation, 515 dichroic, 535/25 
emission), and YFP FRET (430/24 excitation, 515 dichroic, 535/25 emission) filters were used 
for the CFP, YFP, and FRET optical channels.  All excitation filters, dichroic mirrors, and 
emission filters  were from Chroma Technology or Semrock. 
 The following settings were used: exposure time 400-600 msec, 20-30 second 
acquisition rate, 1.3NA 40x oil immersion objective, and excitation light was attenuated with a 
10% neutral density filter. 
In situ FRET Sensor Calibrations.  To calibrate the sensors in cells, a region of interest (ROI) 
was placed on an individual cell and on an untransfected cell or a region in the field of view with 
no cells as a measure of the background fluorescence.  The FRET channel is defined as the 
emission intensity in the acceptor fluorescent protein (FP) channel, upon excitation of the donor.  
The FRET ratio (R) is defined as the background corrected intensity in the FRET channel 
divided by the background corrected intensity in the donor channel, i.e. (IFRET - 
IFRETbackground)/(IDonor - Idonorbackground).  For imaging experiments, media was removed and cells 
ZBD Amino Acid Sequence 
Zap1 Zinc Finger1 = KNNDLKCKWKECPESCSSLFDLQRHLLKDHVSQDFKHP 
Zinc Finger2 = MEPLACNWEDCDFLGDDTCSIVNHINCQHGI 
Zap2 Zinc Finger1 = KNNDLKHKWKECPESCSSLFDLQRHLLKDHVSQDFKHP 
Zinc Finger2 = MEPLAHNWEDCDFLGDDTCSIVNHINCQHGI 
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were washed twice with HHBSS buffer followed by the addition of 1 mL HHBSS.  ROIs were 
followed for 300 seconds to establish a resting R followed by the addition of 150 µM TPEN 
(N,N,N',N'-tetrakis-(2-pyridylmethyl)-ethylenediamine) to chelate Zn2+ and obtain the FRET ratio 
of the unbound sensor (RTPEN).  Once RTPEN was established, cells were washed 3-times with 
the HHBSS solution to remove residual TPEN followed by addition of 1 mL of fresh HHBSS.  
Subsequently, 10 µM ZnCl2 and 7.5 µM digitonin were added to saturate the sensors localized 
to the nucleus and cytosol and establish the FRET ratio of the Zn2+ bound sensor (RZn).  
Alternatively, 10 µM ZnCl2 and 750 nM pyrithione were added to saturate the sensors localized 
to the ER, Golgi, and mitochondria and establish the FRET ratio of the Zn2+ bound sensor (RZn).  
Data were collected at a 30 sec acquisition rate until Zn2+ and digitonin/pyrithione were added, 
at this point the acquisition rate was changed to 20 sec. 
 For all experiments the resting R was converted to a Zn2+ concentration using the 
following equation (21) and the experimentally derived R, RTPEN, RZn, and the published Kd' and 
n values: 
[Zn2+] = Kd' ( 𝑅 − 𝑅𝑇𝑃𝐸𝑁𝑅𝑍𝑛 − 𝑅  )1/n 
Equation 2.1: Equation for converting R into [Zn2+], where 'n' represents the Hill coefficient.  For 
the data reported here, the published values for ZapCY1 (Kd' = 2.5 pM, n = 1.37) and ZapCY2 
(Kd' = 811 pM, n = 0.44) were used.  
For each experiment, RTPEN and RZn were determined for each individual cell in the field of view 
of the microscope. 
2.4 Results 
 2.4.1 Identification of Total Cellular Zinc in Normal vs. Cancerous Prostate Cells  
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 There is a growing consensus that prostate carcinoma is marked by a significant 
reduction in Zn2+ levels.  The majority of studies done to date have revealed that prostate 
cancer exhibits a greater than 50% reduction in total Zn2+ (8-10).  To determine total Zn2+ in the 
recently established prostate cancer cell lines DuCaP and VCaP, we performed ICP-MS to 
compare the differences between RWPE1 normal prostate cell line and LNCaP, a long 
traditional cancer cell line model.  ICP-MS is a technique that measures total ions, in this case 
Zn2+, based on a charge to mass ratio (22, 23).  Figure 2.3 reveals that DuCaP and VCaP 
exhibit a marked reduction in Zn2+ (ng Zinc/mg protein) by well over 50%.  In addition, LNCaP 
also exhibited a significant depletion in Zn2+, consistent with previous studies (10). 
 To continue characterizing total Zn2+ in these cell lines, we performed X-Ray 
Fluorescence Microscopy (XRFM).  This technique detects total Zn2+ in fixed cells (i.e. free plus 
bound Zn2+), but can do so in a spatially resolved manner.  In XRFM, a high energy x-ray beam 
from a synchrotron source is tuned to the K-edge shell of Zn2+, the x-ray beam ejects an 
electron from the core, resulting in release of a photon of light upon relaxation of an L-edge 
electron to the K-edge (24) as depicted in Figure 2.1a.  A schematic representation of 
instrumentation for this experiment is depicted in Figure 2.1b.  Briefly, the X-ray beam is 
rastered across the sample to obtain a map of Zn2+ across a cell.  Zinc in cells was quantified 
using a strip of high resolution Zinc-Telluride, which is a standard used to compare samples.   
 To obtain a distribution map of total Zn2+ in normal and cancerous prostate cells, cells 
were grown on gold formvars, flash frozen and freeze dried to preserve cellular structures.  After 
imaging the cells with light microscopy, samples were subjected to XRFM.  Figure 2.4 depicts 
representative images obtained for LNCaP and RWPE1 cell lines.    Unfortunately, DuCaP and 
VCaP, did not adhere well to formvars and cells were dislodged during the initial plunge freeze.  
On beam line 2-3 the x-ray beam is focused to a 1µm x 1µm spot and hence is not high enough 
resolution to distinguish specific organelles, but rather we were able to observe hot spots  
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Figure 2.3.  ICP-MS of Normal and Cancerous Prostate Cells.  Relative levels of total Zn2+ 
(ng Zn2+/µg protein) in prostate cells.  Cells were digested in low grade nitric acid and Zn2+ was 
measured by ICP-MS.  RWPE cells have significantly higher total Zn2+ than cancer cells 
(ANOVA with Tukey HSD post hoc test).  Each data point represents an individual experiment 
consisting of approximately 400,000 cells per one 10 cm dish of cells.  
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Figure 2.4. XRFM of RWPE1 and LNCaP Cells.  Cells were grown on gold formvar and bright 
field images were taken on a Zeiss Axiovert 200M microscope (top panel).  The white box 
identifies the region over which XRFM data were collected.  High energy x-ray source is tuned 
and focused on sample and rastered across to obtain an elemental map.  As depicted in the 
figure legend to the right, the warmer the color (red) the higher the Zn2+ in the area that the x-ray 
has rastered.  Scale bar represents 10 µm. 
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throughout the cell.  Overall, it appeared that LNCaP cells contained higher levels of total Zn2+, 
but it is important to note that some cellular organelles, such as Zn2+ containing vesicles, could 
not be resolved with this technique.  A zoom-in of some LNCaP cells (lower image, Figure 2.4) 
suggested that perhaps the higher Zn2+ observed in the prostate cancer cell line was 
concentrated in the nucleus.   
 To determine if the LNCaP prostate cancer cell line contained more nuclear Zn2+ than 
RWPE1, cells were fractionated and the nuclear fraction was isolated and subjected to ICP-MS.  
Figure 2.5 demonstrates that the nucleus of LNCaP cancer cell line contains higher total Zn2+ 
than that of RWPE1 normal cell line, corroborating the XRFM results.  To our knowledge this is 
the first study in which total nuclear Zn2+ has been measured and compared amongst a normal 
and cancerous cell line.  Intriguingly, although the cancer cell line exhibits a significant reduction 
in total Zn2+, the nucleus contains elevated Zn2+, indicating that prostate cancer is not simply 
marked by Zn2+ depletion, but rather there is redistribution of Zn2+, suggested more widespread 
dysregulation of Zn2+ homeostasis.   
 2.4.2 Mapping of free Zn2+ in living cells 
 To quantify and map out the differences in free Zn2+ between normal and cancerous 
prostate cells, high affinity FRET sensors that target specific compartments in the cell were 
used. The overall FRET sensor schematic is depicted in Figure 2.2.  This model consists of a 
Zn2+-binding domain (Zap1 or Zap2, Table 2.1) and two fluorescent proteins, cyan fluorescent 
protein (CFP) and citrine fluorescent protein (YFP).  Zn2+ binding to the Zap domain leads to an 
increase in energy transfer from CFP to YFP, thereby increasing the FRET ratio (
𝑌𝐹𝑃 𝐹𝑅𝐸𝑇𝐸𝑚
𝐶𝐹𝑃𝐸𝑚
).    
To map Zn2+ in distinct locations, the ZapCY1 or ZapCY2 sensor was genetically targeted to 
organelles as described previously (18, 19).  Figure 2.6 demonstrates nucleus, cytosol, ER, and 
mitochondria sensor localization in the VCaP cell line.  Because ZapCY1 was saturated at rest  
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Figure 2.5.  ICP-MS of Nuclear Fractions.  Cells were fractionated to separate the nucleus 
and the cytosol to measure the total nuclear Zn2+ content by ICP-MS.  Total Zn2+ as reported by 
ng Zn2+/µg protein, is shown in figure and this data corroborates with XRFM data in which 
nucleus of LNCaP contains more Zn2+ compared to RWPE1 cell line.  Each data point 
represents an individual experiment and ANOVA with Tukey HSD post hoc test was performed. 
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Figure 2.6.  Representative Images of FRET Sensor Localization in VCaP Cells.  The 
following sensors were used: NLS-ZapCY2 (nucleus), NES-ZapCY2 (cytosol), ER-ZapCY1 
(ER), and mitoZapCY1 (mitochondria).  All images depict the FRET channel.  Scale Bar = 25 
µm. 
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in the cytosol (19), we used the lower affinity ZapCY2 in the nucleus and cytosol.  For the ER, 
Golgi, and mitochondria we used the high affinity ZapCY1 (18, 19).  The sensors exhibited 
similar localization in the other cell lines (data not shown).   
To quantify free Zn2+ in cellular compartments, sensors were calibrated in situ using the 
approach outlined in Experimental Methods.  Figure 2.7 depicts representative calibrations for 
the VCaP cell line, demonstrating that treatment with a Zn2+ chelator led to a decrease in the 
FRET ratio, while elevating Zn2+ with a membrane permeabilization agent or an ionophore led to 
an increase in the FRET ratio, as expected.  Other cell lines exhibited analogous behavior when 
subjected to in situ calibrations (data not shown).   
 Using our panel of genetically targeted sensors, we quantified the concentration of free 
Zn2+ in the nucleus, cytosol, ER, and mitochondria using Equation 2.1 and the experimentally 
determined R, RTPEN, and RZn, and the published Kd’ and n values.  The results are presented in 
Figure 2.8.  Our data reveal that in the cytosol of DuCaP, VCaP, and LNCaP cancer cell lines 
free Zn2+ is 100-300 pM compared to 60 pM in normal RWPE1 cell lines.  There results 
demonstrate that the free Zn2+ levels in the cytosol of all three prostate cancer cell line models is 
about 2-5 times higher compared to normal cell line.  The nucleus of DuCaP, VCaP, and LNCaP 
cancer cell lines free Zn2+ is 250-400 pM compared to the RWPE1 normal cell line which is 97 
pM. Therefore in the nucleus we observed that in all three prostate cancer cell lines the free 
Zn2+ levels are 2.5-4 times higher than the normal cell line.  
 Quantification of the free Zn2+ in the ER revealed that the free Zn2+ content is 5.4 pM in 
normal cell line compared to DuCaP (1.1 pM), VCaP (0.7 pM), and LNCaP (0.9 pM).  Thus, the 
free Zn2+ level in RWPE1 is about 4 times higher than all three prostate cancer cell line models.  
In addition, mitochondria of the normal RWPE1 cells contain 4.6 pM free Zn2+ versus DuCaP  
 
50 
 
 
Figure 2.7. Representative in situ Calibration of Localized Sensors in VCaP.  A) Nuclear 
Zn2+ measured using NLS-ZapCY2, B) Cytosolic Zn2+ measure using NES-ZapCY2, C) ER Zn2+ 
measured using ER-ZapCY1, D) Mitochondria Zn2+ measured using ER-ZapCY1.  To calibrate 
these sensors the region of interest is followed for 300 seconds followed by the addition of 150 
µM TPEN to chelate Zn2+.  Once minimum FRET ratio is established TPEN is washed out and 
subsequently 10 µM Zn2+ with 7.5 µM Digitonin (for nucleus and cytosol) or 750 nM Pyrithione 
(ER and mitochondria) permeant is added to saturate the sensor and obtain a maximum FRET 
ratio. 
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Figure 2.8. Free Zinc Concentration in Nucleus, Cytosol, ER, and Mitochondria In Normal 
Versus Cancerous Cell Lines.  A) Concentration of free Zn2+ in the nucleus, B) Concentration 
of free Zn2+ in the cytosol, C) Concentration of free Zn2+ in the ER, D) Concentration of free Zn2+ 
the mitochondria.  In the nucleus and cytosol the free Zn2+ concentration is higher in the 
prostate cancer cell lines (DuCaP, VCaP, and LNCaP) compared to normal prostate RWPE1 
cell line.  In the ER and mitochondria the free Zn2+ concentration is lower in all three prostate 
cancer cell lines in comparison to RWPE1.  Each data point represents an individual cell and 
the data were compiled from a minimum of 4 separate experiments.  ANOVA with Tukey HSD 
post hoc test was performed. 
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(0.8 pM), VCaP (0.8 pM), and LNCaP (1.2 pM) cancer cells, revealing 3-4 times higher Zn2+ in 
the normal cells compared to all three prostate cancer cell lines. 
 We attempted to quantify Zn2+ in the Golgi using Golgi-ZapCY1, but our calibrations 
revealed that the sensor was saturated at rest in all four cell lines (data not shown).  As an 
alternate approach the lower affinity ZapCY2 was targeted to the Golgi but transfections 
routinely failed to result in Golgi-localized fluorescence.   
2.5 Discussion 
   Prostate cancer is one of the most common cancers in men (25) and it is accompanied 
by a high degree of metastasis to bone (25, 26), which correlate with DuCaP and VCaP cancer 
cell line site of metastasis.  Malignant cells in the prostate begin to migrate after matrix 
metalloproteases degrade the extracellular matrix in localized prostate cancer, allowing cells to 
travel through the blood stream invading bone and metastising (25-28).  However, the exact 
molecular mechanism of how prostate cancer arises is still unknown, and clinical diagnostic and 
prognostic markers are flawed.  Diagnostic detection is primarily based on regular examinations 
in which the patient undergoes blood treatment to detect PSA levels.  However, over the last 
few years the value of PSA as a screening method for prostate cancer has diminished due to 
the over diagnosis of this disease (29).  In the last 15 years, more and more studies have 
revealed that there is a significant reduction of Zn2+ that may correlate with disease progression 
(11, 30, 31).  But to evaluate Zn2+ as a potential diagnostic or prognostic marker, it is important 
to have a better understanding of how and why Zn2+ is altered in prostate cancer. To date it is 
still unclear how prostate cells lose their Zn2+ and most importantly it is still unclear whether the 
reduction has consequences for cancer progression. 
 In this study we set out to define the nature of Zn2+ dysregulation in prostate cancer by 
measuring total Zn2+ and generating quantitative maps of the distribution of free Zn2+ amongst 
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intracellular pools.  In addition, we characterized two recently developed prostate cancer cell 
lines DuCap and VCaP.  These cell lines were chosen because of the high degree 
chromosomal and structural abnormalities, comparable to those observed in late-stage 
metastatic tumors, thus adding a more diverse molecular profile to the repertoire of prostate 
cancer cell lines.  In addition, our initial studies revealed that they were depleted of over 50% 
total Zn2+, suggesting they would be good models to study the cellular and molecular 
mechanisms for Zn2+ dysregulation in prostate cancer.   
 Although all three prostate cancer cell lines used in this study were characterized by 
over 50% reduction in total cellular Zn2+, surprisingly we discovered this reduction did not 
translate into across-the-board deficiency in intracellular Zn2+ stores, but rather there was 
substantial redistribution of Zn2+ between subcellular locations.  XRFM provided the first initial 
suggestion that total nuclear Zn2+ might be higher in the LNCaP cancer cell line compared to the 
normal RWPE1 cell line and this was corroborated by ICP-MS on nuclear fractions.  In addition, 
live cell imaging of free Zn2+ revealed that the nucleus and the cytosol of the DuCaP, VCaP, and 
LNCaP cancer cell lines have 2-5x and 0.5-2.5x, respectively higher Zn2+ levels than the 
RWPE1 normal cell line.    
 To date there have been few studies that have revealed or quantified Zn2+ in either the 
nucleus and cytosol.  In our current studies we have elucidated that prostate cancer cell lines 
are depleted of total Zn2+ but free Zn2+ levels in these cell lines is elevated in the cytosol and 
nucleus.  In the cytosol there are a large number of proteins that buffer Zn2+  such as 
metallothionein, which has 17 mammalian isoforms (32).  Some of these isoforms may be over-
expressed in DuCaP, VCaP, and LNCaP cancer cell lines leading to the high free Zn2+ 
concentration in prostate cancer compared to normal cell line RWPE1.  In addition, elevated 
Zn2+ has been proposed to inhibit apoptosis thereby increasing the proliferation rate of cells (33, 
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34).   Elucidating the expression levels of metallothionein between normal and prostate cancer 
cell lines could explain the difference in a higher Zn2+ pool in the cytosol of these cells. 
 We revealed a similar scenario in the nucleus of these prostate cancer cell lines in which 
the free Zn2+ pool is higher compared to RWPE1 normal cell line.  This could be because Zn2+ 
handling and buffering might be different in the nucleus versus the cytosol.  In the nucleus there 
is a large repertoire of transcription factors that bind Zn2+ (5).  Previous studies have shown that 
approximately 25% of total Zn2+ is found in the nuclei of rat liver cells (35).  In addition, Zn2+ is 
bound to chromatin which is the stable complex of DNA and plays a role in DNA replication, 
transcription, and repair (36).  One possible consequence of elevated pools of Zn2+ found in the 
nucleus is that it ensures metallation of the nuclear machinery to aid uncontrolled division.   
 In the ER and mitochondria all three prostate cancer cell lines have a significant 
reduction in the free Zn2+ pool compared to the RWPE1 normal cell line.  The mitochondria is 
the power house of the cell and the site for synthesis of adenosine triphosphate (ATP) (37).  In a 
previous study, mitochondria of prostate cells were isolated  using a sucrose gradient and it was 
revealed that Zn2+ was able to inhibit m-aconitase.  Because m-aconitase converts citrate to 
isocitrate, producing more ATP per each Krebs cycle (2, 38), it was suggested that depletion of 
Zn2+ in the mitochondria would lead to more efficient energy generation, thus fueling cancer 
cells.  In our current studies we determined that the free Zn2+ pool is in the low pM range, which 
is well below to estimated KI for inhibition of m-aconitase.  To assess whether Zn
2+ depletion 
indeed impacts energy production,  it will be necessary to determine the amount of ATP 
production in these cells and compare the results among all four cell lines.  While the free Zn2+ 
pool is low in the prostate cancer cell line models very little is known about how Zn2+ enters the 
mitochondria.  In a more recent study Zn2+ was shown to inhibit cytochrome c release from the 
mitochondria by the direct binding of Zn2+ to H2O2 (Zn
2+-H2O2) (39). 
 In the ER we observed that there is a 2-3 fold reduction in Zn2+ from normal to cancer 
cells which may lead to the improper folding of some proteins.  In the ER it has been found that 
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the Zn2+ is transported into the compartment via the ZnT5 importer while it is exported via the 
hZIP7 transporter (40, 41).  However, very little is known about Zn2+ in the ER of prostate cells.  
To determine if either ZnT5 or hZIP7 are connected with the low levels of Zn2+ in the ER of 
prostate cancer cells it would be necessary to over-express ZnT5 and test whether this 
manipulation causes Zn2+ to be elevated to similar levels of normal prostate cancer cell line.  
Stress to cells induces the unfolded protein response (UPR) in the ER and this has been 
implicated to tumor progression as well as inflammatory bowel disease, bacterial translocation, 
and inflammatory response (42-45).  The UPR and tumor progression could be directly 
correlated with the low Zn2+ in our prostate cancer cell lines models because in HeLa cell line 
chelating Zn2+ with 4-5 µM TPEN for 12 hours induced the UPR response (46). 
 The current study has revealed significant perturbations in Zn2+ between normal and 
cancerous prostate cells.  But it is still unclear how or why these changes arise and what 
implications they have for cancer progression.  The widespread redistribution in Zn2+ suggests 
substantial changes in Zn2+ homeostasis and therefore likely are targets are Zn2+ regulatory 
proteins such as transporters, buffers, and Zn2+-binding proteins.  Indeed, there are a number of 
studies suggesting systematic alterations in Zn2+ transporter levels in prostate cancer (9, 10, 47-
50).  But how such changes influence total and free Zn2+ has yet to be defined.  
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3.1 Abstract 
 The prostate has the highest concentration of Zn2+ in the human body compared to other 
tissues and transformation from normal to cancerous prostate tissue is marked by a significant 
depletion in total Zn2+.  The mechanistic correlation between malignancy and Zn2+ levels is not 
well understood.  To date 24 Zn2+ transporters have been identified.  The two classes of 
transporters are the Zrt-, Irt-like Proteins (ZIP) and Cation Diffusion Facilitators (CDF) also 
referred to as ZnTs.  The ZIP family Zn2+ transporters move Zn2+ from the extracellular space 
into the cytosol and from inside organelles to the cytosol.  On the other hand, the ZnT family 
transporters move Zn2+ from the cytosol to the extracellular space as well as from the cytosol 
into organelles.  In an effort to define how and why Zn2+ is depleted in prostate cancer, we 
establish the changes in expression levels of hZIP1, hZIP2, hZIP3, ZnT1, ZnT2, ZnT4, and 
ZnT7 Zn2+ transporters in a normal prostate cell line (RWPE1) and three prostate cancer cell 
lines (DuCaP, VCaP, and LNCaP).  DuCaP and VCaP are newly established prostate 
carcinoma cell lines with different molecular characteristics than LNCaP and significant 
chromosomal abnormalities that resemble metastatic prostate carcinoma.  We examined the 
mRNA and protein expression levels of the Zn2+ transporters mentioned above by quantitative 
RT-PCR and western blotting respectively, and defined their localization by 
immunofluorescence.  Our data suggest that the regulation of these Zn2+ transporters is altered 
from normal to cancerous cell lines. 
3.2 Introduction 
 Zinc is the second most abundant transition metal in the human body and is critical for 
transcription factors, immune function, and neurotransmission (1-3).  It is estimated that the total 
concentration of Zn2+ in mammalian cells is about 0.1-0.5 mM (4, 5).  Although the majority of 
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cellular Zn2+ is bound by proteins, enzymes, and cellular ligands, labile pools have been 
identified in pancreatic islets cells (6), brain (2), and prostate (7). 
 Peripheral zone prostate tissue accumulates the highest Zn2+ levels in the body 
compared to other soft tissues (7-9).  This zone is also the primary region that undergoes 
malignant transformation and peripheral zone carcinomas are more invasive than those 
originating from the transition zone (10).  Numerous studies have revealed that cancerous 
prostate tissue exhibits dramatically reduced levels of Zn2+ (60-70% lower than in the normal 
peripheral zone) and that the levels of Zn2+ appear to track with progression from benign to 
invasive and metastatic cancers (8, 11-13).  The mechanistic correlation between malignancy 
and Zn2+ levels is not well understood and in particular, it is not clear whether Zn2+ depletion 
contributes to or is a consequence of disease progression. 
 Cellular Zn2+ is regulated in part via transporters that are localized both in the plasma 
membrane and organelles.  These transporters, which include the Zrt-, Irt-like Proteins (ZIP) 
and Cation Diffusion Facilitators (CDF, also referred to as ZnT) move Zn2+ in and out of the cell 
as well as store it in different compartments (5, 14).  Zinc transporters maintain Zn2+ at constant 
homeostatic levels and hence have been the target of a handful of studies to identify the origin 
of Zn2+ depletion in prostate cancer.  To date 24 Zn2+ transporters have been identified, 
including 10 ZnTs and 14 ZIPs.  Some transporters are found in all tissues, while others are 
tissue specific (5, 14, 15).  A schematic representation of some Zn2+ transporter localization is 
depicted in Figure 3.1 In this work we focus on a subset of these transporters (ZnT1, ZnT2, 
ZnT4, ZnT7, hZIP1, hZIP2, hZIP3a, and hZIP3b) which have been implicated in or suggested to 
be involved in Zn2+ regulation in prostate cells.  The rationale for selecting these transporters is 
highlighted below. 
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Figure 3.1.  Schematic of a Cell Showing Zinc Transporters Examined in this Chapter.  
Localization of transporters is specific to each organelle and tissue.  The ZIP family transporters 
move Zn2+ into the cytosol from the extracellular space and organelles while the ZnT family 
transporters move Zn2+ from the cytosol into organelles and export it out of the cell. 
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 The primary importer of Zn2+ for all cell types is hZIP1, but others such as hZIP2 and 
hZIP3 has been suggested to import Zn2+ in prostate cells (14, 16-19). Comparison of mRNA 
levels of the primary Zn2+ importer in human cells, hZIP1, in two model prostate cancer cell lines 
(LNCaP and PC-3) revealed a decrease in hZIP1 in PC-3 compared to LNCaP, suggesting 
heterogeneity among prostate cancer cell lines (12, 17, 20-22).  Comparison of hZIP1 levels in a 
panel of normal and malignant prostate tissue samples revealed a high degree of heterogeneity 
in hZIP1 immunoreactivity, but in general the malignant samples exhibited lower hZIP1 
immunoreactivity, suggesting lower hZIP1 protein levels (12).  hZIP2 and hZIP3 function for the 
re-uptake and conservation of Zn2+ from the prostate fluid and were shown to be down-
regulated in adenocarcinomatous glands, which have lost the ability to accumulate Zn2+ (16). 
 Expression levels of the primary Zn2+ exporter (ZnT1) have also been characterized in 
PC-3 and LNCaP cells, revealing differential regulation of ZnT1 in these two cell lines (23).  The 
ZnT2 transporter is believed to store Zn2+ in lysosomal like compartments of lateral and dorsal 
prostate sections of mice (24, 25).  In the previous two studies quantitative PCR revealed that 
ZnT2 is over-expressed in mouse tissue but no studies have been done using human prostate 
cells to identify the expression level.  While most studies on ZnT2 have been done on mice, the 
prostate gland between mice and humans is different because have humans have three distinct 
tissue sections while mice have four (26).  In addition to ZnT2 storing Zn2+ into lysosomal like 
organelles, ZnT4 has also been proposed to be responsible for concentrating Zn2+ into prostatic 
secretory vesicles and expression levels of this transporter decreased from normal to cancerous 
prostate tissue (27).  ZnT7 Zn2+ transporter is expressed in the intestinal tract, lung, and the 
prostate and is localized to the Golgi apparatus as well as vesicles (28).  This transporter has 
been identified to have a null mutation which leads a decrease in total cellular Zn2+ (29).  These 
studies suggest that dysregulation of Zn2+ transporters may be a consistent feature of prostate 
carcinoma, however it is not clear if a single transporter is primarily responsible for the changes 
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in Zn2+ physiology or whether different prostate cancer cell lines and tumors may be 
characterized by a different perturbation in Zn2+ transporters. 
 One challenge in studying the cellular and molecular characteristics of prostate cancer is 
the limited number of in vitro models (i.e., cell lines) that reflect the diversity of characteristics 
associated with prostate carcinoma (30).  These characteristics include a range of sensitivity to 
hormones (androgen sensitive, responsive, or insensitive), expression of the androgen receptor 
(AR), secretion of prostate specific antigen (PSA), normal and mutated p53 tumor suppressor 
gene, the ability to establish tumors in mice, and the level and complexity of chromosomal 
abnormalities (31).  DU-145, PC-3, and LNCaP prostate cancer cell lines are widely used, yet 
DU-145 and PC-3 do not produce PSA, are androgen insensitive, and do not express AR (31).  
On the other hand, LNCaP produces PSA, expresses a mutated form of AR, expresses wild 
type p53, and is androgen responsive, making it a closer model of prostate carcinoma (32).  
Yet, LNCaP does not develop tumors in mice unless co-injected with stroma (33). 
 Two newly developed prostate cancer cell lines, established from dura matter (DuCaP) 
and vertebra (VCaP) metastases to distinct locations within the same patient (34, 35), have 
recently been characterized (31, 36).  Both cell lines express normal AR, mutant p53, are 
androgen sensitive, produce large quantities of PSA, and are tumorigenic in mice without the 
need to co-inject with stroma (34, 35).  Spectral karyotyping of these lines revealed a large 
number of complex chromosomal abnormalities, consistent with their derivation from late-state 
tumors (36).  To gain insight into the molecular origin of the decreased levels of total Zn2+ 
between normal and prostate cancer cell lines, and the redistribution of free Zn2+ observed with 
organelle-targeted FRET-based sensors, we began establishing how Zn2+ is dysregulated in 
these cell lines, and characterize potential heterogeneity between the diverse cell line models.  
To accomplish this, we measured the mRNA and protein expression levels as well as the 
localization of the Zn2+ transporters mentioned above.  Our results suggest that there is a 
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dysregulation the Zn2+ transporters analyzed in cancerous prostate cells and there is some 
heterogeneity between the prostate carcinoma cell lines. 
3.3 Experimental Methods 
Chemicals and Reagents.  Keratinocyte-serum free media (KSFM), Roswell Park memorial 
Institute (RPMI) 1640 media, and Alexa-Fluor 568 were purchased from Invitrogen-Life 
Sciences (Carlsbad, CA).  ZnT1, ZnT4, ZnT7, hZIP1, hZIP2, and hZIP3 goat-polyclonal 
antibodies and donkey anti-goat IgG-HRP were obtained from Santa Cruz Biotechnology (Santa 
Cruz, CA).  RNeasy Mini Kit and Omniscript Reverse Transcriptase Kit were obtained from 
Qiagen (Valencia, CA).  SYBR Green PCR Master Mix was purchased by Applied Biosystems.  
Zinc chloride, low metal grade nitric acid, and β -actin mouse monoclonal antibody were 
purchased from Sigma Aldrich.  Amersham ECL PlusTM Western Blotting Detection Reagent 
and Polyvinylidene Fluoride (PVDF) membrane were obtained from GE Amersham.  Ready 4-
20% gradient Tris-HCl Gels and 10X Tris/Glycine/SDS premixed electrophoresis buffer were 
obtained from Bio-Rad.  Bicinchoninic acid assay protein kit and Surfact-Amps* NP-40 
Detergent Solution were purchased from Pierce (Rockford, IL).  Electron Microscopy grade 
paraformaldehyde and Fluoromount-G (for immunofluorescence) were purchased from Electron 
Microscopy Sciences (Hatfield, PA). 
Microscopy.  Fixed samples stained with antibody-Alexa-Fluor 568 were imaged using on a 
Nikon A1-R Confocal system on an Eclipse Ti-E PFS Microscope using a 60X Plan Apo VC, 
numerical aperture of 1.4.  Nikon images were analyzed with NIS-Elements software.  In 
addition we also used a Zeiss Laser Scanning Microscope (LSM) 510 confocal with 3 photon-
multiplier tubes, 60X oil objective, and a numerical aperture of 1.4.  Zeiss LSM images were 
analyzed with ZEN 2009 software.  All fluorescent images obtained on a given microscope 
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system were thresholded to the same intensity in order to highlight the relative fluorescent 
intensity unless indicated. 
Cell Culture.  RWPE1 (normal prostate cell line), VCaP, and LNCaP (prostate cancer cell lines) 
were obtained from the American type Cell Collection (ATCC).  DuCaP was a kind gift from Dr. 
Scott M Lucia at the University of Colorado Health Sciences Center (Denver, CO).  RWPE1 
cells were culture in Keratynocyte-Serum Free Media (KSFM) supplemented with 0.05 mg/mL 
bovine pituitary extract, 5 ng/mL epithelial growth factor (Life Sciences), 100 U/mL penicillin and 
100 µg/mL streptomycin.  DuCaP, VCaP, and LNCaP cell lines were cultured in Roswell Park 
Memorial Institute (RPMI) media (Life Sciences) supplemented with 10% (v/v) fetal bovine 
serum (Atlanta Biologicals), L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin.  All 
cell lines were incubated at 37ºC with 5% CO2, changing the media every 2-3 days. 
Zinc Chloride Incubation.  Because the presence of phosphates causes Zn2+ to precipitate out 
of solution, all Zn2+ incubation studies were done in phosphate free HEPES-Hanks' Balanced 
Salt Solution (HHBSS) (1.26 mM CaCl2, 5.36 mM KCl, 984 µM MgCl2, 137 mM NaCl, 16.65 mM 
D-Glucose, and 30 mM HEPES).  Buffers were generated with Chelex-100 treated water (Sigma 
Aldrich).  Incubations were done at 37°C with 5% CO2 for 2 hours prior to imaging and mRNA or 
protein extraction. 
Immunohistochemistry.  To observe localization of ZnT1, ZnT4, hZIP1, hZIP2, and hZIP3 Zn2+ 
transporters, cells were grown to approximately 70% confluency on cover slips in 12-well plates.  
A set of cells was grown in normal media conditions and another set incubated with Zn2+ prior to 
fixation as mentioned above.  Cells were briefly washed with Phosphate Buffered Saline (PBS) 
pH 7.4 and fixed with 3.7% paraformaldehyde in PBS for 20 minutes followed by 
permeabilization using 0.1% Triton X-100 in PBS for 20 minutes.  Blocking was done using 3% 
BSA in PBS for 1 hour at room temperature.  Primary antibodies were diluted in blocking buffer 
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50-fold (1:50) and incubated for 1 hour followed by 2-3 PBS washes.  Secondary AlexaFluor 
conjugated antibody was diluted 1000-fold (1:1000) in blocking buffer.  After secondary antibody 
incubation, cells were washed with PBS two times and mounted onto cover slides using 
Fluoromount-G and left in a dark environment at room temperature overnight. 
Total RNA Isolation and Quantitative Reverse Transcription Polymerase Chain Reaction 
(qRT-PCR).  To measure mRNA levels of each transporter under normal growth conditions and 
Zn2+ incubation, cells were grown to 90% confluency and collected by scraping cells and placing 
them into a 15 mL conical tube followed by a 5 minute spin at 5000 rpm at room temperature.  
Following spin, supernatant was removed carefully without disturbing cell pellet  and total RNA 
was extracted using RNeasy Kit supplemented with RNase-free DNase solution as per 
manufacturers' instructions.  DNase was added to ensure pure total RNA sample.  Total RNA 
was quantified by diluting RNA 10-fold (1:10) in 10 mM Tris•Cl, pH 7.5 and the absorbance at 
260 nm and 280 nm was measured.  Blank measurements were performed using 10 mM 
Tris•Cl, pH 7.5. The ratio of (A260/A280) was calculated to ensure a pure RNA sample with a ratio 
between 1.9-2.1.  After RNA quantification, 100 ng of total RNA was used to perform RT-PCR 
and obtain the cDNA of each cell line using QIAGENs Omniscript RT Kit.  The RT-PCR step 
consisted of a 10 minute incubation at 25°C to allow proper annealing of a random primer 
followed by a 70 minute incubation at 37°C, and finally a 5 minute incubation at 95°C to 
inactivate the polymerase.  For primers, annealing temperature, and size of fragment refer to 
Table 3.1. 
Melt Curve Analysis and PCR Percent Efficiency.  To characterize the integrity of the primers 
of the cDNA for each cell line, the Melt Curve of the reference genes (Homo sapiens tubulin, 
alpha 1b (K-ALPHA-1) and Homo sapiens hypoxanthine phosphoribosyltransferase 1 (HPRT1)) 
was done by performing a primer matrix reaction.  K-ALPHA-1 and HPRT1 were chosen 
because studies have revealed that housekeeping genes such as GAPDH, β -actin, and 18S- 
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Table 3.1. Quantitative Polymerase Chain Reaction Primers. 
 
*Primers were designed in our laboratory using NCBI Primer-Blast and selection included the 
criterion that the primers span Exon-Exon junctions. 
 
 
 
 
 
 
 
 
 
Transporter Primer Sequence Annealing 
Temperature (°C) 
Size (bp) 
ZnT1 CCTCGTCGCTGGCGATGCTC (FWD) 
TTTCTGGGTCTGCGGGGTCCAA (REV) 
60 537 
ZnT2 AGTCCCGCGCGCAACTTTCA (FWD) 
TGTGCCAGGTACCCACCAACGA (REV) 
60 360 
ZnT4 CTAGAAGGTGTGCCAAGCCATTTGA (FWD) 
GCACTGTCAGGCTGGGGCAA (REV) 
59 449 
ZnT7 TCAGAGGGTACAGCAGTTGCAAGG (FWD) 
AACGGCTGACTCTACCCCGT (REV) 
58 348 
hZIP1 GCACGTGACGCTCCAGTTCCC (FWD) 
GAGCTGCACCCAGCCCGATG (REV) 
60 470 
hZIP2 AGCCAGAGGTCATCACCGGCTA (FWD) 
AGCAAGGCAGAGCTGCACGG (REV) 
59 487 
hZIP3a AGCCAGAGGTCATCACCGGCTA (FWD) 
AGCAAGGCAGAGCTGCACGG (REV) 
59 487 
hZIP3b CCCCCGGGAGTTGCTGGACTGAG (FWD) 
GGCCATAAGGTGCCAAGGGCTG (REV) 
61 389 
Reference 
Gene 
   
Kβ 1 GGCCCCGCCCTAGTGCGTTA (FWD) 
GGTGCACTGGTCAGCCAGCTT (REV) 
60 496 
HRTP1 GCAGCCCTGGCGTCGTGATTA (FWD) 
CGTGGGGTCCTTTTCACCAGCA (REV) 
60 499 
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   Table 3.2. Reference Gene Primer Matrix 
 
 
 
 
 
 
 
 
 
 
 
 
RNA demonstrate different behavior in various tissue types as well as treatments within the 
same tissue (37, 38).  Both, K-ALPHA-1 and HPRT1, reference genes have been shown to not 
change from normal to cancerous prostate cells (39) making them ideal reference genes to 
normalize the expression of the Zn2+ transporters being studied.  Briefly a series of qPCR 
reactions were performed using different forward and reverse primer concentrations (Table 3.2).  
To perform qPCR a CFX96 BioRad Thermocycler was used with the following conditions: Initial 
95°C for 10 minutes to start polymerase, denaturation at 95°C for 30 seconds, annealing at 
55°C for 40 seconds, and extension at 72°C for 35 seconds.  PCR was set for 65 cycles 
followed by a Melt Curve Analysis from 55-95°C with 0.5°C increments for 5 seconds incubation 
per increment.  Analysis is plotted as fluorescence output of SYBR Green as a function of 
temperature increase as illustrated in Figure 3.2.  Figure 3.2 represents the K-ALPHA-1 
reference gene using DuCaP prostate cancer cell line and demonstrates a single peak, 
indicating that the reaction yielded one product, and hence the reaction demonstrates good 
gene specificity.  Both, K-ALPHA-1 and HPRT1, yielded similar results on all four cell lines using  
      Forward Primer (nM) 
Reverse Primer (nM) 50 300 900 
50 50/50 300/50 900/50 
300 50/300 300/300 900/300 
900 50/900 300/900 900/900 
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Figure 3.2.  Melt Curve Analysis Confirms Gene Specificity.  The primer matrix yielded a 
peak that demonstrates robust amplification of desired product as detailed by the single peak at 
approximately 85°C.  The DuCaP prostate cancer cell line was used in this representation and 
qPCR was performed on an CFX96 BioRad Thermocycler.  The legend within the graph 
represents forward and reverse primer concentrations in nM. 
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900 nM forward and 300 nM reverse primers concentration.  After analyzing all data sets we 
decided to use 900 nM forward and 300 nM reverse primer concentrations because the primer 
matrix using all cell lines with the reference genes yielded best specificity with these primer 
concentrations, because other combinations of concentrations yielded multiple peaks, indicative 
of non-specificity or primer-dimer products. 
 Once forward and reverse primer concentrations were determined, a PCR percent 
efficiency was carried out to ensure that the amount of DNA is doubled per cycle.  A serial 
dilution of cDNA of all cell lines was done from 1:10 to 1:10,000.  This serial dilution ensures 
that there is equal coverage of the range of quantification being performed and ensures that 
there are no pipeting errors.  In addition we need to ensure that we obtain a linear relationship 
between the amount of template and the Ct-value to ensure accurate and reproducible 
quantification of all samples.  The Ct-value is defined in a quantitative PCR as the number of 
cycles needed for the SYBR Green fluorescent output to cross the threshold (i.e., background 
levels).  These experiments utilized a hard-shell thin-wall 96-well skirted PCR plate and 3 µL of 
template cDNA was used per reaction.  The Ct-value was plotted as function of serial dilution, as 
depicted in Figure 3.2, generating a standard curve.  Figure 3.3 shows a slope of -3.4504 
which is used to calculate the amplification efficiency using E = 10(-1/slope) or denoted as % 
Efficiency = (E-1) x 100%.  For the representative plot the efficiency of amplification is 1.95 
which means that for every cycle of the PCR the template number is increased by 1.95 fold or 
95% of the template was amplified.  Optimal qPCR conditions should have between 90-105% 
amplification efficiency and using both reference genes and all four cell lines we were able to 
obtain this range of efficiency. 
Protein Isolation and Western Blotting.  Cells were grown to 90% confluency in normal media 
conditions.  One set of cells was grown under normal media conditions and another set was 
incubated with 50 µM ZnCl2 for 2 hours prior to collecting cells.  Cells were briefly washed with  
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Figure 3.3.  Standard Curve of qPCR to Calculate Percent Efficiency of Reaction.  This 
application defines the efficiency of a qPCR based on a serial dilution of cDNA.  Homo sapiens 
tubulin, alpha 1b (TUBA1B), Kα 1 Reference Gene is shown.  Serial dilution was done from 
1:10  to 1:10,000.  Amplification efficiency is calculated from the slope of the line using:             
E = 10(-1/slope).  The amount of DNA should double with every cycle in the PCR and the 
amplification efficiency will denote this.  The efficiency for a good PCR should be within 90-
105%.  In this example the percent efficiency is 95%. 
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ice-cold PBS pH 7.4, followed by scraping the cells with 2 mL of PBS onto 2 mL eppendorf 
tubes.  Cells were then centrifuged for 5000 rpm for 5 minutes at 4°C.  Approximately 400-900 
µL of Lysis buffer (150 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA pH 8.0, 1% Triton X-
100, and 0.2% NP040 plus protease inhibitor cocktail) was used to extract proteins.  Following 
lysis, tubes were incubated in ice for 20 minutes, centrifuged for 20 minutes at 14,000 rpm at 
4°C, and supernatant was collected.  A BCA assay was performed to quantify protein and 90 µg 
of protein was loaded per lane to resolve on acrylamide Tris-HCl gel. 
 For resolution and detection of each Zn2+ transporter, a 4-20% gradient gel was used 
and resolved at 130 Volts until the dye front ran out of the gel, followed by transfer onto a PVDF 
membrane at 300 mA for 90 minutes in 10% methanol transfer buffer at 4°C.  Following transfer, 
the PVDF membrane was washed in TBS-Tween (TBST, 0.05% Tween-20) for 15 minutes in 
the cold room, and incubated in blocking buffer containing 5% dry milk in TBST overnight at 
4°C.  Each membrane was then incubated with ZnT1, ZnT4, ZnT7, hZIP1, hZIP2, or hZIP3 
goat-polyclonal antibody at a 1:200 fold dilution in 1% milk-TBST for 1 hour at room temperature 
followed by 3-washes with TBST.  Donkey anti-goat IgG-HRP secondary antibody at a 1:10,000 
fold dilution was incubated in 1% milk-TBST for 1 hour at room temperature followed by 3-
washes with TBST.  The ECL reagent was used as specified by manufacturers' instructions and 
blots exposed. 
 Once detection of specified protein was observed, blots were stripped using 67.5 mM 
Tris-HCl pH 6.8, 2% SDS, and 100 mM DTT.  Blots were placed in shaker using gentle agitation 
for 10-15 minutes at room temperature followed by 15-20 minute TBST wash.  Blots were 
blocked as specified above and β -actin probing done using a 1:6000 fold dilution and rabbit anti-
mouse IgG-HRP secondary antibody at a 1:20,000 fold dilution.  Both primary and secondary 
antibodies were diluted in 1% milk-TBST. 
77 
 
3.4 Results 
 3.4.1 Decreased Cellular Zinc in Prostate Cancer Cell Lines 
 There is a growing consensus that prostate carcinoma is marked by a significant 
reduction in Zn2+ levels.  While LNCaP, PC-3, DU-145, and RWPE2 cells lines have been 
extensively examined (12, 13, 21, 23), Zn2+ levels and regulatory proteins have not been 
characterized for the newly developed DuCaP and VCaP cell lines.  Therefore we sought to 
define these parameters and compare the results with the more commonly used LNCaP, and a 
normal prostate cell line RWPE1.  In Chapter II, we defined total cellular Zn2+ in all four cell 
lines by ICP-MS and found that DuCaP and VCaP are significantly reduced of Zn2+ compared to 
the normal cell line.  Similar results have been observed for other prostate cancer cell lines such 
as PC-3 and RWPE2 (13, 21). 
 3.4.2 Expression Levels and Localization of hZIP1 Zn2+ Transporter 
 hZIP1 is a 36 kDa protein, ubiquitously expressed at the membrane and is primarily 
responsible for import of Zn2+ from the extracellular matrix into the cytoplasm of prostate cells  
(17).  Figure 3.4.A shows no difference in the mRNA level of hZIP1 in cancerous vs. 
noncancerous cell lines grown under normal media conditions, as measured by qPCR.  
However, western blot analysis shows an increase in hZIP1 protein levels in the cancerous cell 
lines (Figure 3.4.B), suggesting that in these cancer cell lines perhaps hZIP1 protein is up-
regulated to compensate for the loss of Zn2+.  Comparable levels of hZIP1 were observed in 
DuCaP, VCaP, and LNCaP. 
 hZIP1 expression has been shown to be regulated by Zn2+, where high extracellular Zn2+ 
leads to a decrease in protein expression, perhaps to minimize accumulation of excess Zn2+ 
(13).  To explore whether Zn2+ regulation of hZIP1 differs in normal vs. cancerous cell lines, 
cells were incubated with 50 µM ZnCl2 for 2 hours prior to mRNA and protein extraction.  Under 
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these conditions there was a decrease in mRNA expression level for RWPE1 and DuCaP post-
Zn2+ incubation (18% and 52% decrease in mRNA expression, respectively), while no change 
was observed for VCaP and LNCaP.  On the other hand, a significant decrease in hZIP1 protein 
level was observed in RWPE1 cells, consistent with the finding of Huang et al., (13).  
Conversely, the cancer cell lines exhibited an increase in hZIP1 protein levels in response to 
Zn2+ treatment (Figure 3.4.B), suggesting aberrant Zn2+-dependent transporter regulation in all 
three cancerous cell lines.  The increase in hZIP1 protein level was greatest in the LNCaP cell 
line. 
 Given the altered level of hZIP1 protein and perturbed regulation by extracellular Zn2+, 
we examined hZIP1 localization by immunofluorescence.  As shown in Figure 3.4.C, under 
normal growth conditions hZIP1 is primarily localized to the plasma membrane in all four cell 
lines, consistent with previous studies on RWPE1, LNCaP, and PC-3 cell lines (12, 13).  There 
is also some localization to fluorescent punctae, consistent with vesicular localization, primarily 
at the cell periphery.  The images in Figure 3.4.C are thresholded to the same intensity level, 
revealing the greater expression of hZIP1 in the prostate cancer cell lines, consistent with the 
western blotting results.  Treatment of cells with extracellular Zn2+ did not give rise to a 
significant change in hZIP1 localization (Data Not Shown). 
 3.4.3 Expression Levels and Localization of hZIP2 Zn2+ Transporter 
 hZIP2 is a 33kDa protein and is expressed at the membrane of specific cell types such 
as prostate, uterus, cervical epithelium, monocytes, and optic nerve (16, 40).  It has been found 
to bring Zn2+ into the cell by measuring uptake of 65Zn in transfected K562 erythroleukemia cells 
expressing hZIP2 (18).  Figure 3.5.A shows that under normal growth conditions in DuCaP and 
VCaP prostate cancer cells hZIP2 mRNA is elevated compared to RWPE1 by1176% and 
1000%, respectively, and no difference is observed in the LNCaP cell line compared to normal  
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Figure 3.4. qRT-PCR, Western Blot, and Immunofluorescence of hZIP1.  A) Quantitative RT-PCR analysis reveals that there is 
no difference in the mRNA level of hZIP1 between RWPE1 and the three cancer cell lines, when cells are grown under normal 
growth conditions.  After incubating the cells with Zn2+ for 2h prior to total RNA extraction, hZIP1 mRNA is down-regulated in RWPE1 
and DuCaP cell lines by 138% and 63%, respectively.  Each qRT-PCR data point represents one 10 cm dish of cells.  Relative 
mRNA levels were corrected to the Kβ 1 reference gene  B) Western blot analysis reveals that all three prostate cancer cell lines have 
higher hZIP1 expression compared to RWPE1 normal cell line.  After incubating cells with Zn2+, there is a decrease in expression in 
RWPE1, but an increase in all three cancer cell lines.  C) Immunofluorescence reveals that hZIP1 localizes to the plasma membrane.  
All fluorescent images were thresholded to the same intensity, scale Bar = 25 µm, and arrow denotes localization on cell.  ANOVA 
with Tukey HSD post hoc test was performed for qRT-PCR. 
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Figure 3.5. qRT-PCR, Western Blot, and Immunofluorescence of hZIP2.  A) Quantitative 
RT-PCR analysis reveals that hZIP2 mRNA expression is low in RWPE1 and LNCaP cell lines 
compared to DuCaP and VCaP.  DuCaP and VCaP cancer cell lines express 168% and 163% 
more mRNA compared to RWPE1.  After incubating the cells with Zn2+ for 2h prior to total RNA 
extraction, there is no change in mRNA levels for RWPE1, DuCaP, and VCaP cell lines but a 
81% decrease in LNCaP. Each qRT-PCR data point represents one 10 cm dish of cells.  
Relative mRNA levels corrected to Kβ 1 reference gene.  B) Western blot analysis reveals that 
RWPE1, DuCaP, and LNCaP cell lines express similar levels of hZIP2 protein and a higher level 
than the LNCaP cell line.  After incubating cells with Zn2+, the hZIP2 protein levels in DuCaP 
and LNCaP increase while the expression levels of RWPE1 and VCaP remain the same.  C) 
Immunofluorescence analysis reveals that hZIP2 protein localizes to the plasma membrane.  
Incubating cells with Zn2+ did not reveal that transporter localizes to another region of the cell 
but is retained at the membrane (Data Not Shown).  All fluorescent images were thresholded to 
the same intensity, scale Bar = 25 µm, and arrow denotes localization on cell.  ANOVA with 
Tukey HSD post hoc test was performed for qRT-PCR. 
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cell line RWPE1.  Under the same conditions, Western blot analysis (Figure 3.5.B) revealed 
that RWPE1, DuCaP, and VCaP cell lines express comparable amounts of protein which is 
consistently higher than the LNCaP cell line.  These results confirm that hZIP2 is present in the 
prostate lines and reveals that there is some heterogeneity in expression.  There is not a 
consistent trend between the cancerous and noncancerous cells.   
 Very little is known about whether hZIP2 mRNA expression or localization is regulated 
by Zn2+.  There was no change in mRNA expression level for RWPE1, DuCaP, and VCaP cell 
lines, but a decrease of 42% in for LNCaP upon treatment with Zn2+.  Conversely, at the protein 
expression level DuCaP and LNCaP protein levels increased while VCaP exhibited a decrease 
and RWPE1 did not change.  These results suggest that while Zn2+ does not substantially affect 
the expression level of mRNA, it affects the protein expression levels of all three cancer cell 
lines and again heterogeneity is observed in how Zn2+ elevation impacts protein expression 
levels. 
 Given the altered expression level of hZIP2 mRNA and protein level we examined the 
localization of hZIP2 localization by immunofluorescence.  As shown in Figure 3.5.C under 
normal growth conditions hZIP2 is primarily localized at the plasma membrane of all four cell 
lines, as well as in punctae at the cell periphery.  All images in this panel are thresholded to the 
same intensity level, revealing greater expression of hZIP2 in the prostate cancer cell lines, 
similar to hZIP1.  Treatment of cells with extracellular Zn2+ did not give rise to a significant 
change in hZIP2 localization (Data Not Shown). 
 3.4.4 Expression Levels and Localization of hZIP3 Zn2+ Transporter 
 hZIP3 is a 34 kDa protein and in human prostate tissue is localized at the plasma 
membrane (16) but has not been characterized to a great extent other than identifying that it is 
responsible for Zn2+ accumulation in K562 erythroleukemia cells using 65Zn (18).  When primers 
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were designed for quantitative analysis of the mRNA in our cell line, two alternatively spliced 
isoforms were predicted by the NCBI Nucleotide-BLAST.  These two isoforms, hZIP3a and 
hZIP3b, have a distinct C-terminus and hZIP3b is shorter compared to hZIP3b by 212 amino 
acids, giving rise to a 34 kDa and 11 kDa protein respectively.  Due to this we decided to 
measure and quantify the mRNA expression levels of both if detectable.  Figure 3.6.A and 
3.6.B reveal marked differences in the expression level of both isoforms.  For hZIP3a, DuCaP 
and VCaP mRNA is higher compared to RWPE1, 1176% and 1000%, respectively and for the 
hZIP3b isoform, DuCaP and VCaP prostate cancer cell lines express lower levels of mRNA than 
RWPE1 ( 46% and 75%decrease, respectively).  Our current antibody detects only the 34 kDa 
protein (hZIP3a isoform) (Figure 3.6.C).    Western blot analysis reveals that hZIP3 protein is 
expressed higher in RWPE1 compared to the cancer cell lines, this band has been consistent 
with the 34 kDa isoform.   
 To explore whether Zn2+ regulation of hZIP3 differs in normal compared to cancerous 
cell lines, cells were incubated with 50 µM ZnCl2 for 2 hours prior to mRNA and protein 
extraction.  Figure 3.6.A reveals that hZIP3a mRNA expression is not altered by Zn2+ for 
RWPE1, DuCaP, and VCaP cell lines but it decreases mRNA expression in LNCaP cell line 
by32%.  On the other hand, hZIP3b expression decreases for RWPE1 (22%), DuCaP (59%), 
and LNCaP (44%) while no change is observed for VCaP cell line.   
 Given the difference in expression level of hZIP3 between mRNA and protein in all four 
cell lines we examined the localization of this transporter in our cell lines by 
immunofluorescence.  As observed in Figure 3.7 under normal growth conditions hZIP3 is 
located at the plasma membrane of all four cell lines.  But similar to hZIP1 and hZIP2 a 
fluorescent signal is observed in punctae as well.  In RWPE1 and VCaP cell lines the 
fluorescent signal is uniform at the membrane and very few punctae are visible.     
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Figure 3.6. qRT-PCR and Western Blot of hZIP3a and hZIP3b.  A) Quantitative RT-PCR 
analysis reveals that mRNA expression of hZIP3a is low in RWPE1 and LNCaP cell lines while 
expression is higher in DuCaP and VCaP by 168% and 163%, respectively.  Incubating cells 
with Zn2+ for 2 hours prior to total RNA extraction revealed that hZIP3a mRNA expression levels 
did not change for RWPE1, DuCaP, and VCaP cell line while mRNA levels decreased by 100% 
for the LNCaP cell line.  B) qRT-PCR of hZIP3b demonstrates that mRNA expression level is 
lower in DuCaP and VCaP compared to RWPE1.  After incubating the cells with Zn2+ for 2h prior 
to total RNA extraction mRNA expression levels for hZIP3b decreased in RWPE1, DuCaP, and 
LNCaP but not for VCaP cell line.  Each qRT-PCR data point represents one 10 cm dish of 
cells.  Relative mRNA levels were corrected to the Kβ 1 reference gene.  C) Western blot 
analysis shows that RWPE1 cell lines exhibit higher protein expression compared to DuCaP, 
VCaP and LNCaP.  After incubating cells with Zn2+ we observe that hZIP3 protein expression is 
regulated by Zn2+.  DuCaP protein expression increases, while in RWPE1 and VCaP there is a 
decrease in expression.  ANOVA with Tukey HSD post hoc test was performed for qRT-PCR. 
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Figure 3.7.  Immunofluorescence of hZIP3.  hZIP3 is primarily localized to the plasma membrane.  Under normal media conditions 
most hZIP3 is found at the periphery of the cell but there is some staining of punctae.  In particular DuCaP and LNCaP puncta are 
found at the membrane.  After incubating cells with Zn2+ hZIP3 is more uniform along the membrane and less puncta are observed at 
the periphery as well.  hZIP3 localization is altered after Zn2+ from puncta to more membrane localization.  Scale Bar = 25 µm, and 
arrow denotes localization on cell.  All images were thresholded to the same intensity. 
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 3.4.5 Expression Levels and Localization of ZnT1 Zn2+ Transporter 
 ZnT1 is a 60 kDa Zn2+ transporter located at the plasma membrane and on vesicles (41) 
which functions in exporting Zn2+ out of the cell.  As observed in Figure 3.8.A, about the cancer 
cells exhibit decreased ZnT1 mRNA levels compared to RWPE(71% for DuCaP, 64% for VCaP 
and LNCaP). While qPCR reveals that mRNA expression is low in all three cancer cell lines the 
protein expression does not correlate with mRNA and in all three cancer cell lines the protein 
expression level is higher than RWPE1, as shown in Figure 3.8.B.  DuCaP and LNCaP express 
higher levels of ZnT1 than VCaP signifying heterogeneity within cancer cell lines.  Because 
ZnT1 exports Zn2+ from the cell, the higher levels in cancer cells could signify one mechanism 
for reducing Zn2+ levels in cancer cell lines. 
 To determine whether Zn2+ regulates the mRNA and protein expression of ZnT1, cells 
were treated with 50 µM extracellular Zn2+ for 2 hours prior to extractions.  Figure 3.8.A shows 
that Zn2+ treatment changes the mRNA expression level of RWPE1, DuCaP, and VCaP by 
decreasing expression in normal cell line by 19% and increasing expression in DuCaP (275%) 
and VCaP (700%).  There were no significant mRNA expression changes in LNCaP cell line, 
consistent with previous studies (20, 23).  Because of slight variations in protein loading, it is 
harder to discern a pattern for ZnT1 protein levels, but it appears there may be subtle increases 
in ZnT1 protein levels upon Zn2+ treatment.  There was no significant difference in Zn2+ 
regulation between the normal and cancerous cell lines. 
 To examine whether the localization of ZnT1 was altered in prostate cancer cell lines, 
transporter localization was examined by immunofluorescence.  In all three cancer cell lines, 
ZnT1 was observed on the membrane and intracellular vesicles as observed in Figure 3.8.C.  
Subtle differences were observed in the localization in cancer cell lines.  In DuCaP and VCaP, 
the majority of ZnT1 was found at the membrane and vesicles located at the cell periphery, 
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whereas LNCaP showed a much greater portion of vesicular localization, perhaps because 
LNCaP exhibits the highest ZnT1 protein expression of all the cell lines.  These results suggest 
heterogeneity in the prostate cancer cell lines.  It was difficult to detect plasma membrane or 
vesicular localization in RWPE1 cells, perhaps because of the lower ZnT1 protein expression 
levels.  Addition of extracellular Zn2+ did not cause a significant change in localization (Data Not 
Shown). 
 3.4.6 mRNA Expression Levels of ZnT2 Zn2+ Transporter 
 ZnT2 is thought to have two splice isoforms which produce two different protein species 
with molecular weights 42 and 35 kDa (42).  The 35 kDa Zn2+ transporter lacks part of the N-
terminus producing a shorter isoform of ZnT2.   It has been proposed that these two isoforms of 
ZnT2 may have different physiological functions, because one isoform localizes to the plasma 
membrane and the other to secretory compartments (42, 43).  But because we were interested 
in defining the mRNA of ZnT2 localized to vesicles we decided to quantify the 42 kDa isoform.  
Many studies have measured the mRNA expression level of ZnT2 in mouse or rat prostate (24, 
25, 44, 45), but no studies have examined the mRNA or protein expression in human cells.  The 
tissue specificity of ZnT2 is restricted to small intestine, liver, pancreatic acinar cells, kidney, 
and mammary gland with subcellular localization in vesicles and secretory granules (14).  
Because ZnT2 lacks a good specific antibody we decided to only measure the mRNA 
expression level. 
 Figure 3.9 reveals that the mRNA expression in DuCaP and VCaP cancer cell lines is 
higher than RWPE1 and LNCaP.  The increase in mRNA expression for DuCaP is 500% and 
VCaP is 400% higher than RWPE1.  Although we were able to detect mRNA coding for ZnT2, 
the relative mRNA expression is significantly lower compared to other transporters studied.  To 
determine whether Zn2+ regulates the mRNA and protein expression of ZnT2, cells were treated  
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Figure 3.8. qRT-PCR, Western Blot, and Immunofluorescence of ZnT1.  A) Quantitative RT-PCR analysis reveals that mRNA 
expression is high in RWPE1 compared to DuCaP, VCaP, and LNCaP by 111% for DuCaP and 94% for VCaP and LNCaP.  After 
incubating the cells with Zn2+ for 2h prior to total RNA extraction, in RWPE1 there is a 135% decrease in mRNA expression while in 
DuCaP and VCaP mRNA levels increase by 93% and 150%, respectively.  Each qRT-PCR data point represents one 10 cm dish of 
cells.  Relative mRNA levels were corrected to Kβ 1 reference gene.  B) Western blot analysis reveals that DuCaP, VCaP, and 
LNCaP cell lines exhibit higher protein levels than RWPE1.  After incubating cells with Zn2+, ZnT1 protein expression does not 
change.  C) Immunofluorescence analysis reveals that ZnT1 localizes to the plasma membrane.  Incubating cells with Zn2+ did not 
reveal that transporter localizes to another region of the cell but is retained at the membrane (Data Not Shown).  All fluorescent 
images were thresholded to the same intensity, scale Bar = 25 µm, and arrow denotes localization on cell.  ANOVA with Tukey HSD 
post hoc test was performed for qRT-PCR. 
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Figure 3.9. qRT-PCR Analysis of ZnT2.  qRT-PCR revealed that ZnT2 mRNA expression 
levels are low in RWPE1 and LNCaP compared to DuCaP and VCaP.  DuCaP mRNA is 133% 
and VCaP mRNA is 120% higher compared to RWPE1.  Incubating the cells with Zn2+ for 2h 
prior to total RNA extraction revealed no change in ZnT2 mRNA expression level for RWPE1 
and DuCaP but a 100% increase for VCaP and 100% decrease for LNCaP.  Each qRT-PCR 
data point represents one 10 cm dish of cells.  Relative mRNA levels corrected to Kβ 1 reference 
gene.  ANOVA with Tukey HSD post hoc test was performed for qRT-PCR. 
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with 50 µM extracellular Zn2+ for 2 hours prior to extractions.  Figure 3.9 shows that Zn2+ 
treatment increases the expression level in VCaP (by 300%), but decreases the expression 
level in LNCaP (by 33%).  For RWPE1 and DuCaP there was no significant change in 
expression post-Zn2+ treatment.  
 3.4.7 Expression Levels and Localization of ZnT4 Zn2+ Transporter 
 ZnT4 is a 47 kDa protein that is primarily localized to intracellular vesicles of prostate, 
mammary, and small intestine cells (14, 27, 46).  Henshall and coworkers (27) measured ZnT4 
protein levels in prostate tumor samples of over 100 patients, and found decreased ZnT4 
protein levels in malignant tissues.  Figure 3.10.A and 3.10.B demonstrate that the mRNA level 
is higher in VCaP (1389%) and LNCaP (1667%) and the protein level is higher in all 3 cancer 
cell lines compared to the normal RWPE1 cells, with LNCaP exhibiting the highest protein levels 
of all cell lines.  Incubation of cells with Zn2+ for 2 hours did not yield significant changes in the 
protein levels, suggesting that ZnT4 expression levels are not regulated by Zn2+ during the time 
frame examined.  However, DuCaP mRNA expression level decreased by 43%, post-Zn2+.  
ZnT4 has been shown to be associated with vesicles and membrane, similar to ZnT2 and ZnT3 
Zn2+ transporters that are associated with vesicles in the small intestine and neurons, 
respectively (14, 27, 46).  In all prostate cell lines, there was a strong ZnT4 fluorescent signal 
associated with punctae, consistent with vesicular localization as demonstrated in Figure 
3.10.C (top panel).  The levels of ZnT4 protein were higher in all three cancer cell lines. 
 To explore whether localization was regulated by Zn2+, we observed ZnT4 localization 2 
hours after incubating the cells with 50 µM ZnCl2.  Figure 3.10.C (lower panel) demonstrates 
that RWPE1 cells show a decrease in vesicular localization and an increase in membrane 
localization.  Conversely DuCaP and VCaP show very little change upon incubation with Zn2+, 
while LNCaP displays an increase in vesicular localization.  Combined these results suggests 
 92 
 
aberrant Zn2+-dependent regulation of ZnT4 (cancer cells respond differently than the 
noncancerous cell line) and differential regulation in the prostate carcinoma lines.   
 3.4.8 Expression Levels of ZnT7 Zn2+ Transporter 
 ZnT7 is a 42 kDa protein that is primarily localized to the Golgi apparatus and vesicles in 
prostate, lung and small intestine and highly expressed in the proximal segment of the small 
intestine facilitating Zn2+ transport from the cytoplasm to the Golgi (28, 29).  Figure 3.11.A and 
3.11.B  show that the mRNA of ZnT7 is expressed at similar levels in all cell lines.  However, 
western blot analysis shows an increase in ZnT7 protein levels in RWPE1 (Figure 3.11.B), 
while all cancer cell lines express lower levels of protein with LNCaP expressing the least 
amount.  Incubation of cells with Zn2+ for 2 hours did not yield significant changes in the mRNA 
in RWPE1, DuCaP, and VCaP cell line, but gave rise to a small decrease in expression in 
LNCaP of 31%.  Western blot analysis reveals that aberrant Zn2+-dependent regulation of ZnT7 
occurs in all four cell lines.  In Figure 3.11.B protein levels are highly regulated by Zn2+ because 
in RWPE1, DuCaP, and VCaP protein expression levels decrease, while in cancer cell line 
LNCaP ZnT7 is slightly up-regulated from endogenous levels.  Given the drastic changes in 
protein expression we sought to perform immunofluorescence to observe its localization but 
experiments were futile because we did not clearly observe Golgi localization (Data Not Shown). 
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Figure 3.10. qRT-PCR, Western Blot, and Immunofluorescence of ZnT4.  A) Quantitative 
RT-PCR analysis reveals that mRNA expression is low in RWPE1 compared to VCaP, and 
LNCaP by 173% and 177%, respectively.  After incubating the cells with Zn2+ for 2h prior to total 
RNA extraction there is no change in mRNA expression level in RWPE1, VCaP, and LNCaP 
while there is a 80% decrease in mRNA expression in DuCaP.  Each qRT-PCR data point 
represents one 10 cm dish of cells.  Relative mRNA levels corrected to Kβ 1 reference gene.  B) 
Western blot analysis reveals RWPE1, DuCaP and, VCaP cell lines have similar protein levels 
while LNCaP expresses more protein.  After incubating cells with Zn2+, ZnT4 protein expression 
does not change.  C) Immunofluorescence analysis reveals that most of the ZnT4 localizes to 
vesicles in RWPE1 while in DuCaP, VCaP and LNCaP prostate cancer cell lines it localized at 
the plasma membrane and some vesicles.  Incubating cells with Zn2+ reveals changes in ZnT4 
localization.  Lower panel demonstrates that plasma membrane localization of ZnT4 increases 
for RWPE1 but decreases for DuCaP, VCaP, and LNCaP which show more vesicular staining.  
Image within RWPE1 (normal growth condition) fluorescence was increase to demonstrate 
vesicle signal.  All fluorescent images were thresholded to the same intensity, scale Bar = 25 
µm, and arrow denotes localization on cell.  ANOVA with Tukey HSD post hoc test was 
performed for qRT-PCR. 
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Figure 3.11. qRT-PCR and Western Blot of ZnT7.  A) Quantitative RT-PCR analysis reveals no differences between the cell lines.  
Incubating the cells with Zn2+ for 2h prior to total RNA extraction does not lead to any changes in RWPE1, DuCaP, and VCaP while 
there is a 104% decrease in LNCaP cell line.  Each qRT-PCR data point represents one 10 cm dish of cells.  Relative mRNA levels 
corrected to Kβ 1 reference gene.  B) Western blot analysis reveals that in  RWPE1 ZnT7 protein expression is higher compared to 
DuCaP and VCaP cell lines while LNCaP expression was undetectable.  After incubating cells with Zn2+, RWPE1 protein expression 
decreases, DuCaP appears to have no change, VCaP protein expression decreases, and LNCaP protein expression increases 
slightly.  ANOVA with Tukey HSD post hoc test was performed for qRT-PCR. 
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3.5 Discussion 
 The American Cancer Society estimates that there are 241,740 new cases of prostate 
cancer per year in the United States, approximately 28,170 of which result in death 
(http://www.cancer.org/Cancer/ProstateCancer/OverviewGuide/prostate-cancer-overview-key-
statistics).  Early detection of prostate cancer requires regular examinations along with blood 
work to detect serum prostate specific antigen (PSA) (47).  Elevation of serum PSA, also known 
as human kallikrein 3, is a widely used marker to monitor prostate health and malignancy.  
Unfortunately, benign tumors and some forms of inflammatory prostate disease can lead to 
elevated serum PSA and may result in false positive diagnosis of prostate cancer (48-50), 
conversely PSA levels can appear normal in patients with prostate cancer.  Moreover, PSA 
levels do not correlate with the aggressiveness of the cancer and hence are not always reliable 
predictors of prognosis (51, 52). 
 Due to the need for more reliable diagnostic and prognostic prostate cancer markers, a 
growing number of studies have suggested the use of Zn2+ as a potential biomarker in the 
progression of this disease (22, 53-55).  To evaluate this possibility, it is essential to better 
characterize Zn2+ levels and regulation in cell lines (in vitro models), animals models, and tissue 
samples from patients at different stages of malignancy.  Because prostate cancer is 
characterized by a high degree of heterogeneity at the molecular level, we set out to define the 
levels of Zn2+ as well as key regulatory proteins in two newly developed prostate cancer cell 
lines that derived from different metastases from the same patient. 
 In previous Chapters we report that DuCaP, VCaP, and LNCaP prostate cancer cell 
lines are depleted of over 50% total cellular Zn2+ compared to normal cell line.  While these cell 
lines are markedly depleted of cellular Zn2+ it did not translate across the board in all organelle 
but rather we found a redistribution of Zn2+.  Both nucleus and cytosol in the prostate cancer cell 
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line models contain a higher pool of free Zn2+ compared to normal cell line.  On the other hand, 
the ER and mitochondria were markedly depleted of free Zn2+ in all three prostate cancer cell 
line models compared to normal cell line RWPE1.  These differences in Zn2+ suggest that the 
Zn2+-regulatory proteins might be expressed differently between our cell line models. 
 Examination of the mRNA levels, proteins, and protein localization of six Zn2+ 
transporters revealed significant differences between the cancer and noncancerous cell lines, 
suggesting widespread dysregulation of Zn2+ homeostasis in prostate carcinoma.  In this study 
we examined 7 out of 24 known Zn2+ transporters and we suspect examination of a broader 
spectrum of Zn2+ regulatory proteins will yield further differences between normal and cancer 
cells.  These 7-Zn2+ transporters (hZIP1, hZIP2, hZIP3, ZnT1, ZnT2, ZnT4, and ZnT7) were 
chosen because they all have been suggested to be regulated differently in either prostate 
tissue or cell carcinoma, but there are no comprehensive studies that compare mRNA levels, 
protein levels, localization, and dependence of expression on Zn2+ treatment.  Moreover, few 
studies examine multiple cell lines, making it difficult to assess whether observed differences 
reflect heterogeneity in transporter expression or a systematic change associated with the 
cancer phenotype. 
 Very little is known about regulation of Zn2+ transporter expression levels.  Our results 
show substantial differences between the mRNA expression levels measured by qRT-PCR and 
protein levels measure by western blotting. In fact, for six of the seven transporters analyzed we 
did not observe a direct correlation of mRNA and protein expression levels, suggesting that 
expression must be regulated post transcriptionally and/or post-translationally and revealing that 
relative mRNA levels tell us little about the relative levels of protein in cells.  There is some 
evidence that some Zn2+ transporters are glycosylated.  For example, in mammary gland tissues 
ZnT1 has two N-linked and two O-linked glycosylations (43).  But otherwise there is very little 
information on post-translational modifications that might be present that could influence levels 
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of stability.  As noted below, for many transporters we observed modulation of protein levels 
upon treatment of cells with Zn2+ for two hours, suggesting that transporter expression may be 
altered by Zn2+ status and environmental conditions.  There is precedent for this in the literature 
as in the intestine of mice hZIP4 is internalized and degraded in response to Zn2+ (56).   
Our initial intent in pursuing these studies was to answer two questions: 1) do cancer 
cells yield a consistent “Zn2+ dysregulation phenotype” or is there substantial heterogeneity 
among the Zn2+ regulatory proteins and 2) do changes in Zn2+ transporters track with changes in 
the free or total Zn2+ levels observed in normal versus cancerous cells.  With regard to the first 
question, there are some systematic differences in transporters across all cancer cell lines, but 
there is also substantial heterogeneity.  For example, both hZIP1 and ZnT1, the primary 
importer and exporter, respectively, are expressed higher in DuCaP, VCaP and LNCaP cancer 
cell lines compared to RWPE1.  The increased expression of ZnT1 protein in prostate cancer 
cell lines could lead to enhanced extrusion of Zn2+ and hence lower total cellular Zn2+ levels.  On 
the other hand, the high protein expression of hZIP1 in the prostate cancer cell lines suggests 
that perhaps hZIP1 is upregulated to compensate for the low Zn2+ levels.  hZIP3 protein levels 
are lower in all three cancer lines compared to RWPE1.  Similarly, the ZnT4 protein expression 
level is elevated in all three cancer cell lines.  ZnT4 is primarily localized to vesicles and the 
plasma membrane.  Qualitatively, it appeared as if ZnT4 exhibited increased plasma membrane 
localization in the cancer cell lines, but this needs to be explored more systematically and 
quantitatively.  If this turns out to be the case, perhaps increased levels of ZnT4 facilitate 
extrusion of Zn2+ from cells, lowering total Zn2+ levels. 
 Because little is known about regulation of Zn2+ transporters in mammalian cells, at the 
outset of the study we weren’t sure whether transporters would be sensitive to levels of free 
Zn2+ or total Zn2+.  Our observation of ZnT1 protein in the prostate cancer cell lines could be 
interpreted two ways.  One interpretation is that increased ZnT1 may lead to enhanced 
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extrusion of Zn2+, which would correlate with the lower total Zn2+ observed in cancer cell lines.  
Alternatively, ZnT1 expression levels may be regulated by Metal Transcription Factor-1 (MTF-1) 
“sensing” free Zn2+ in the cytosol.  Studies have shown that MTF-1 is regulated by high levels of 
Zn2+ in the cytosol to increase ZnT1 expression as well as expression of the buffer regulatory 
protein metallothionein (MT) (57-59).  While we observe high Zn2+ content in the cytosol of these 
prostate cancer cell lines using FRET sensors it could be possible that high Zn2+ is affecting 
MTF-1 hence leading to the high expression ZnT1 that we observe in all three prostate cancer 
cell lines.   
We also observe substantial differences among the cancer cell lines.  For example  
hZIP2 expression is higher in DuCaP and VCaP compared to RWPE1, but there is almost no 
protein detected in LNCaP cells, demonstrating heterogeneity between these cancer cell lines.  
ZnT7 localizes to Golgi and the protein expression varies in all four cell lines.  In the last chapter 
we tried to quantify the free Zn2+ levels in the Golgi but found that our sensor was saturated in 
this compartment in normal and cancer cell lines.  This may signify that the Zn2+ levels in the 
Golgi are not controlled by ZnT7.   
Finally, complicating analysis of transporter expression is the fact that that Zn2+ 
transporters may be influenced by environmental Zn2+ levels.  In this study when cells were 
treated with Zn2+ for 2 hrs, we saw many changes in protein levels, although often we did not 
observe a consistent trend amongst the prostate cancer cell lines. For example, Zn2+ treatment 
led to changes in protein levels for ZnT7, hZIP2, and hZIP3, but there was no consistent trend 
between the cancerous and noncancerous cell lines.  Alternatively, for ZnT4 there was no 
change in expression upon treatment and for ZnT1, the blots were difficult to interpret because 
of differential loading.  However, an interesting trend was observed for hZIP1 in RWPE1 Zn2+ 
caused a dramatic down-regulation of the this transporter similar to previous observations (13), 
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whereas protein levels actually increased in all three cancer cell lines, suggesting overall 
dysregulation of Zn2+ homeostasis..   
 In conclusion, our results demonstrate marked differences in mRNA and protein 
expression levels and localization of 7-Zn2+ transporters.  While some of the differences occur 
systematically across all cancer cell lines, others don’t.  Although all three prostate cancer cell 
lines exhibit a similar Zn2+ phenotype (depletion of total Zn2+ and redistribution of free Zn2+), it is 
hard to determine which Zn2+ transporter may be responsible for the altered Zn2+ levels, 
particularly when we have only profiled a subset of the transporters.  This is perhaps not 
surprising given the heterogeneity in molecular characteristics of these cell lines.  Heterogeneity 
in Zn2+ transporters has also be observed in studies characterizing hZIP1 and ZnT4 in a panel 
of tumor cells Costello and coworkers observed a high degree of heterogeneity in hZIP1 in 22 
prostate tissue samples although malignant samples generally showed lower levels of hZIP1 tan 
normal samples (12).  Moreover, a study characterizing hZIP2 and hZIP3 in normal and benign 
prostate hyperplasia (BPH) demonstrates that these transporters are downregulated in 
malignant cells (16), consistent in our observation for hZIP2 in LNCaP cancer cell line and 
hZIP3 in DuCaP and VCaP.  In order to fully probe the mechanistic correlation of these 
transporters to Zn2+ levels and distribution in these cell lines, functional assays are required to 
determine whether the explicit changes observed in transporter expression lead to changes in 
Zn2+. 
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4.1 Abstract 
 
 Genetically encoded sensors based on fluorescence resonance energy transfer (FRET) 
are powerful tools for reporting on ions, molecules and biochemical reactions in living cells.  
Here we describe the development of new sensors for Zn2+ based on alternate FRET-pairs that 
do not involve the traditional CFP and YFP.  Zn2+ is an essential micronutrient and plays 
fundamental roles in cell biology.  Consequently there is a pressing need for robust sensors to 
monitor Zn2+ levels and dynamics in cells with high spatial and temporal resolution.  All the 
existing sensors are comprised of CFP and YFP and hence have limited utility in acid 
compartments and don't permit simultaneous imaging of Zn2+ fluxes in multiple cellular 
locations.  Here we develop a suite of sensors using alternate FRET pairs, including 
tSapphire/TagRFP, tSapphire/mKO, Clover/mRuby2, mOrange2/mCherry, and 
mOrange2/mKate.  These sensors were targeted to both the nucleus and cytosol and 
characterized and validated in living cells.  Sensors based on the new FRET pair 
Clover/mRuby2 displayed a higher dynamic range and better signal-to-noise ratio than the 
remaining sensors tested and were optimal for monitoring changes in cytosolic and nuclear 
Zn2+.  Using a green-red sensor targeted to the nucleus and cyan-yellow sensor targeted to 
either the ER, Golgi, or mitochondria, we were able to monitor Zn2+ uptake simultaneously in 
two compartments, revealing that nuclear Zn2+ rises quickly, whereas the ER, Golgi, and 
mitochondria all sequester Zn2+ more slowly and with a delay of 600-700 sec.  Lastly, these 
studies provide the first glimpse of nuclear Zn2+ and reveal that nuclear Zn2+ is buffered at a 
higher level than cytosolic Zn2+. 
4.2 Introduction 
 Fluorescent proteins (FP) are powerful tools to monitor cellular signals.  Since the initial 
development of GFP as a research tool for biological discovery, laboratories have diversified FP 
spectra through directed evolution, resulting in a plethora of probes across the visible spectrum 
(1).  These FPs have been used in the generation of fluorescence resonance energy transfer 
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(FRET)-based sensors to report dynamic biochemistry in living cells (2, 3).  Because FRET 
efficiency is sensitive to distance and orientation between the donor and acceptor fluorophore, 
conformational changes due to binding of a ligand to a protein of interest can form the basis of 
FRET-based biosensors.  The most commonly used donor and acceptor FPs are variants of 
cyan FP (CFP) and yellow FP (YFP) (2).   
 In recent years the development of alternate color FRET sensors has enabled new 
avenues of research such as the ability to monitor a single signal in multiple cellular 
compartments or simultaneously track two cellular signals (4).  For example, two 
complementary probes for caspase-3 activity based on mTFP1/mCitrine and 
mAmetrine/tdTomato were used to visualize caspase-3 activity in the nucleus and cytoplasm, 
revealing temporal differences in caspase-3 activation (5).  The same FRET pairs were used to 
develop probes for monitoring both Ca2+ and caspase-3 in the same cell (6).  Monomeric Teal 
FP (mTFP) is an FP version of the widely used CFP derived a s replacement for enhanced CFP 
because of its high quantum yield (7).  Such studies allow researchers to precisely correlate the 
timing of two interdependent cellular events or to track the movement of ions or molecules from 
one compartment to another.  An additional advantage of alternate color FRET sensors, 
particularly those that avoid using a variant of YFP which is quenched by acid (8), is that they 
are likely to be less sensitive to pH perturbations. 
 While in principle the concept of generating alternate color FRET sensors is attractive, in 
practice there are a number challenges that have limited availability of non-CFP/YFP 
biosensors.  First and foremost, the vast majority of the > 120 FRET-based biosensors currently 
available are based on CFP/YFP and as noted in a recent publication (6), changing the FPs 
often requires extensive re-optimization of the sensor.  Secondly, the biophysical (folding, 
maturation, oligomerization state) and photophysical properties (brightness) of red and orange 
FPs still lag behind those of the cyan-yellow counterparts (9), making it challenging to identify a 
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robust alternate FRET pair.  Indeed of the non-CFP/YFP biosensors developed thus far, each 
research team chose a different combination of FRET partners (5, 10-14). 
 In this work, we developed alternately colored Zn2+ biosensors, testing a series of green-
red and orange-red FP combinations.  Because it is common for sensors to exhibit diminished 
responses in cells compared to in vitro (15, 16), we screened the panel of sensors in 
mammalian cells to assess whether they were capable to responding to manipulation of cellular 
Zn2+ levels. The sensors were then targeted to both the nucleus and cytosol and nuclear 
sensors were used in conjunction with an organelle-localized CFP-YFP-based Zn2+ sensor to 
monitor Zn2+ fluxes in two cellular compartments simultaneously.  We believe these represent 
an important breakthrough in expanding the palette of Zn2+ sensors and developing sensors for 
use in acidic compartments. 
4.3 Experimental Methods 
FRET Sensor Cloning.  A schematic of the general sensor construction is presented in Figure 
4.1a and all sequences have been deposited in GenBank.  Table 4.1 summarizes the mutations 
in the zinc finger domain.  For bacterial expression and sensor purification, sensor cDNA was 
cloned into pET302/NT-His (Life Technologies) in which the BamHI and EcoRI restriction sites 
were reversed by site directed mutagenesis.  For mammalian cell expression sensor cDNA was 
cloned into pcDNA3.1-(+) between BamHI and EcoRI.  To localize sensors to either the nucleus 
or the cytosol, a nuclear localization (NLS) or nuclear exclusion (NES) signal sequence was 
cloned upstream of BamHI site, such that the signal sequence is at the N-terminus of the 
sensor.  For nuclear or cytosolic localization the following primers were used: 5’-
ATGCCTAAAAAAAAACGTAAAGTTGAAGATGCTGGATCC-3’ (NLS) and 5’-
ATGCTTCAACTTCCTCCTCTTGAACGTCTTACTCTTGGATCC-3’ (NES).  Sensors containing 
localization sequences for endoplasmic reticulum, Golgi apparatus, and mitochondria were 
developed previously (15, 17). 
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Figure 4.1.  Nuclear Localization and Nuclear Exclusion Signal Sequence constructs.  A 
NLS and NES signal sequence were cloned into pcDNA 3.1 (+) vector upstream BamHI.  A) 
Schematic of FRET sensor construct.  B) Representative images of transfected sensor showing 
localization to either the nucleus or cytosol. Scale bar = 20 µm. 
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Table 4.1. Amino acid sequence of Zap Zinc Binding Domains (ZBD) 
ZBD Amino Acid Sequence 
Zap1 KNNDLKCKWKECPESCSSLFDLQRHLLKDHVSQDFKHPMEPLACNWEDCDFLGDDTCSIVNHINCQHGI 
Zap1.1 KNNDLKHKWKECPESCSSLFDLQRHLLKDHVSQDFKHPMEPLACNWEDCDFLGDDTCSIVNHINCQHGI 
Zap2 KNNDLKHKWKECPESCSSLFDLQRHLLKDHVSQDFKHPMEPLAHNWEDCDFLGDDTCSIVNHINCQHGI 
Zap1 disassociation constant (Kd') = 2.53 pM; Zap2 (Kd') = 811 pM; Zap1.1 (Kd') = undetermined 
 
 
 
 
 
 
 Clover lacks the C-terminal residues GITLMDELYK that are present in other GFP-based 
proteins.  During the initial cloning of ZapCmR1 there was an inadvertent addition of the linker 
MVSKGEEL to the N-terminus of mRuby2 so the sensor contains this additional linker. 
Cell Culture and Microscopy. HeLa cells were grown in Dulbecco's Modified Eagle's Medium 
(DMEM) (Life Technologies) supplemented with 10% (v/v) fetal bovine serum (Atlanta 
Biologicals), 100 U/mL penicillin, and 100 µg/mL streptomycin.  Cells were incubated at 37°C in 
5% CO2, changing the media every 3 days.  Once cells were approximately 80-90% confluent 
they were split and seeded onto 3.5 cm imaging dishes until they were approximately 40-50% 
confluent.  At this point 1 µg of sensor DNA was transiently transfected using TransIT®-LT1 
(Mirus) as specified by manufacturer instructions. 
 Forty-eight hours after transfection, cells were imaged using phosphate, calcium, and 
magnesium free HEPES-buffered Hanks' balanced salt (HHBSS) media (5.36 mM KCl, 137 mM 
NaCl, 16.65 mM D-Glucose, and 30 mM HEPES) pH 7.4.  This buffer is made in our laboratory 
because phosphates are known to precipitate Zn2+.  Buffer was generated with Chelex-100-
treated water (Sigma Aldrich).  Cell imaging was performed on a Zeiss Axiovert 200 M 
microscope with a Cascade 512B CCD camera (Roper Scientific) and Xenon arc lamp (XBO75) 
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using MetaFluor software (Universal Imaging) to operate the system. All excitation filters, 
dichroic mirrors, and emission filters (Chroma Technology or Semrock) are presented in Table 
4.2.  The following settings were used: exposure time 400 msec, 20-30 second acquisition rate, 
1.3NA 40x oil immersion objective, and excitation light was attenuated with either a 10% neutral 
density filter for tSapphire paired with mKO or TagRFP as well as for Clover and mRuby2 and 
5% neutral density filter for mOrange2 paired with mCherry or mKate as well as for CFP-YFP 
pair. 
Live cell imaging experiments.  To characterize sensors in cells, a region of interest (ROI) 
was placed on an individual cell and on an untransfected cell or a region in the field of view with 
no cells as a measure of the background fluorescence.  The FRET channel is defined as the 
emission intensity in the acceptor FP channel, upon excitation of the donor.  The FRET ratio is 
defined as the background corrected intensity in the FRET channel divided by the background 
corrected intensity in the donor channel, i.e. (IFRET - IFRETbackground)/(IDonor - Idonorbackground).  For 
imaging experiments, DMEM media was removed and cells were washed twice with HHBSS 
buffer followed by the addition of 1 mL HHBSS.  ROIs were followed for 300 seconds to 
establish a resting R followed by the addition of 150 µM TPEN (N,N,N',N'-tetrakis-(2-
pyridylmethyl)-ethylenediamine) to chelate Zn2+ and obtain the FRET ratio of the unbound 
sensor (RTPEN).  Once RTPEN was established, cells were washed 3-times with the HHBSS  
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Table 4.2. Filter sets and dichroic mirrors used for cellular imaging 
FP Excitation filter (nm/bandwidth) Dichroic (nm) 
Emission filter 
(nm/bandwidth) 
CFP 430/24 455 470/24 
YFP 495/10 515 535/20 
tSapphire 390/22 495 510/20 
mKO 540/25 565 595/50 
TagRFP 540/25 565 595/50 
mOrange2 540/25 565 595/50 
mCherry 577/20 595 630/60 
mKate 577/20 595 630/60 
Clover 480/20 495 510/20 
mRuby2 540/25 565 595/50 
   
For FRET experiments, the donor excitation filter and dichroic mirror are used along with the emission filter of the 
acceptor FP. 
 
 
 
 
 
 
 
solution to remove residual TPEN followed by addition of 1 mL of fresh HHBSS.  Subsequently, 
135 µM ZnCl2 and 10 µM digitonin were added to saturate the sensor and establish the FRET 
ratio of the Zn2+ bound sensor (RZn).  Data were collected at 20-30 sec acquisition rate.  The 
dynamic range of each sensor was defined as the maximum FRET ratio divided by the minimum 
FRET ratio (Rmax/Rmin), and the percent saturation was calculated according to [(|R-RTPEN|)/(|RZn-
RTPEN|)]*100%. 
Simultaneous monitoring of Zn2+ uptake into multiple compartments.  In order to monitor 
Zn2+ in two compartments of a single cell, cells were transfected with both a cyan-yellow and 
green-red or red-orange FRET sensor.  Zinc uptake was initiated by addition of 100 µM ZnCl2 
extracellularly without any ionophores or membrane permeabilization agents.  Previous studies 
116 
 
in our lab have established that addition of 100 µM ZnCl2 extracellularly leads to a rise in 
cytosolic Zn2+ from ~ 100 pM to ~ 6 nM (15).  The background corrected FRET ratio was 
measured for each compartment as described above. 
4.4 Results 
 4.4.1 Measurement of spectral bleedthrough.  Given the lack of consensus on an 
optimal green-red or red-orange FRET pair, we decided to test 5 different alternate FRET pairs 
in the zinc sensor platform.  Table 4.3 summarizes the sensors generated using tSapphire, an 
ultra-violet (UV) excitable FP (18), Clover (19), mKO (20), mOrange2 (21), TagRFP (22), 
mCherry (23), mKate (24), or mRuby2 (19).  An important consideration when evaluating 
whether multiple FRE sensors can be used simultaneously in cells is the extent of spectral 
crosstalk between individual FPs and FRET constructs.  Spectral crosstalk generally refers to 
the presence of fluorescence signal from more than one species in a single optical channel.  
The extent of crosstalk is given by the percent bleedthrough (or contamination) of a given 
fluorescent species in an optical channel.  Because FRET ratios are calculated using the FRET 
optical channel and the donor optical channel, we felt it was important to determine 
bleedthrough in both of these channels.  For the donor channel, HeLa cells were transfected 
with cDNA encoding an individual FP and the fluorescence intensity was measured in all 
channels.  Table 4.4 and Figure 4.2 and 4.3 present the percent bleedthrough in each of the 
donor channels (CFP, tSapphire, mOrange2, and Clover), which was less than 5% in all cases.  
For the FRET channel constructs in Table 4.5 were transfected into cells and the intensity was 
measured in each of the FRET channels (Figure 4.4).  When pairing CFP-YFP with a green-red 
sensor, there was substantial bleedthrough of Clover-mRuby2, tSapphire-TagRFP and 
tSapphire-mKO into the CFP-YFP FRET channel (50%, 96%, and 80%, respectively), and < 
10% of CFP-YFP into the green-red channels.  This indicates that if one of these green-red 
sensors is to be used alongside a CFY-YFP sensor, the sensors need to be in non-overlapping  
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Table 4.3. Fluorescent Protein Excitation and Emission 
Donor FP Acceptor FP Sensor Name Excitation max 
(nm) 
Emission max 
(nm) 
CFP YFP ZapCY2 435 535 
tSapphire mKO ZapSM2 399 559 
tSapphire TagRFP ZapSR2 399 580 
mOrange2 mCherry ZapOC2 549 610 
mOrange2 m ZapOK2 Kate 549 633 
Clover mR ZapCmR1 uby2 486 605 
Clover mR ZapCmR1.1 uby2 486 605 
Clover mR ZapCmR2 uby2 486 605 
Sensor nomenclature is as follows: Zap refers to the 1st two zinc fingers of the Saccaromyces cerevisiae Zap1 
transcription factor that serves as the zinc binding domain, the next two letters refer to the donor and acceptor FPs, 
finally the “1” at the end of a sensor name indicates the wild type Zap1 domain was used, the “2” indicates that two 
mutations (Cys to His) were incorporated to lower the zinc affinity, as outlined in [15].  “1.1” indicates one mutation 
(Cys to His) was incorporated. 
 
   
 
 
spatial locations. Spectral crosstalk was minimized by pairing CFP-YFP with an orange-red 
sensor (< 3% for all combinations). 
 4.4.2 Generation of nuclear and cytosol localized constructs 
 There are no published sensors for quantitatively measuring Zn2+ in the nucleus.  Yet 
nuclear Zn2+ is an important component of cellular Zn2+ homeostasis.  First, a large number of 
nuclear proteins, including polymerases, transcription factors, and DNA remodeling factors such 
as histone deacetylases require Zn2+ for proper function (25, 26).  Second, there is evidence 
that the primary Zn2+ storage protein, metallothionein, shuttles into the nucleus during the G1 to 
S phase transition, suggesting dynamic regulation of nuclear Zn2+ during cell division (27).  
Third, studies have reported the generation of transient nuclear Zn2+ signals (28).  Therefore, we 
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Table 4.4. Percent Bleedthrough of Fluorescent Proteins 
 
 
Each experiment was performed in triplicate and a minimum of 6-cells per field of view were observed. Values reported represent the mean ± SEM.  Excitation 
filters, Dichroic mirrors, and Emission filters for each channel are given in Table 4.2.  Percent intensity was calculated as follows: Intensity in the designated 
channel divided by Intensity in the channel of the transfected FP.  Cross-talk between the donor channels is highlighted in gray. 
 
 
Transfected 
FP 
Percent intensity in each channel1 
 Clover 
channel 
CFP channel YFP channel tSapphire channel mKO/mOrange2/TagR
FP/mRuby2 
channel 
mCherry/mKATE 
channel 
CFP 15 ± 0.06 100 0.06 ± 0.01 3 ± 0.03 0.09 ± 0.01 0.06 ± 0.01 
YFP 41 ± 0.6 0.02 ± 0.003 100 0.06  ± 0.001 5 ± 0.3 0.01 ± 0.01 
tSapphire 16 ± 0.06 4 ± 0.06 27 ± 0.2 100 0.01 ± 0.03 0.3 ± 0.03 
mKO 2 ± 0.4 0.4 ± 0.05 4 ± 0.07  100 2 ± 0.08 
mOrange2 0.2 ± 0.01 0.3 ± 0.01 4 ± 0.05 0.07 ± 0.01 100 4 ± 0.02 
TagRFP 0.09 ± 0.01 0.6 ± 0.08 0.3 ± 0.03 0.1 ± 0.01 100 22 ± 0.04 
mCherry 0.16 ± 0.02 0.4 ± 0.02 0.06 ± 0.01 0.08 ± 0.01 57 ± 0.1 100 
mKate 0.35 ± 0.03 0.5 ± 0.02 2 ± 0.01 0.2 ± 0.01 43 ± 0.3 100 
Clover 100 0.3 ± 0.03 84 ± 5.3 0.2 ± 0.01 0.3 ± 0.001 0.06 ± 0.004 
mRuby2 3 ± 0.3 8 ± 1 2 ± 0.2 0.3 ± 0.07 100 44 ± 0.1 
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Figure 4.2. Bleed-through of fluorescent proteins.  Representative images for bleedthrough 
measurements.  Cells were transfected with the FP listed on the left hand side and the 
excitation and emission parameters used as shown on top.  Ex = Excitation and Em = Emission 
and bandwidth in nanometers.  Scale bar = 20 µm. 
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Figure 4.3. Bleed-through of fluorescent proteins.  Representative images for bleedthrough measurements.  Cells were 
transfected with the FP listed on the left hand side and the excitation and emission parameters used as shown on top.   
Ex = Excitation and Em = Emission and bandwidth in nanometers.  Scale bar = 20 µm. 
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Figure 4.4. Cross-talk of FRET sensors.  Representative images for bleedthrough 
measurements.  Cells were transfected with the FRET sensor listed on the left hand side and 
the excitation and emission parameters used as shown on top.  Ex = Excitation and Em = 
Emission and bandwidth in nanometers.  Scale bar = 20 µm. 
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Table 4.5. Percent Bleedthrough of sensor into FRET channels 
Transfected 
Sensor 
Percent intensity in emission channels below upon direct excitation of the transfected FRET 
Sensor1 
 Cyan-yellow tSapphire-mKO tSapphire-TagRFP 
mOrange2-mCherry 
mOrange2-mKate Clover-mRuby2 
ZapCY2 100 4.7 ± 0.02 2.17 ± 0.01 9.4 ± 0.1 
ZapSM2 80 ± 1 100 ≥  100 37 ± 0.3 
ZapSR2 96 ± 2 100 ≥  100 31 ± 0.2 
ZapOC2 2 ± 0.2 3.5 ± 0.1 100 17.5 ± 0.4 
ZapOK2 2.3 ± 0.1 2.8 ± 0.1 100 17 ± 0.3 
ZapCmR1 50 ± 1 11 ± 0.2 ≥  100 100 
 
Each experiment was performed in triplicate and a minimum of 4-cells per field of view were observed.  Values 
reported represent the mean ± SEM.  Cells were transfected with FRET sensor listed in the left column.  The sensors 
were excited with their respective excitation filters and the emission intensity in each of the channels on the right 
hand side was measured.  Excitation filters, Dichroic mirrors, and Emission filters for each channel are given in Table 
4.2.  Percent intensity was calculated as follows: Intensity of the designated channel divided by Intensity in the 
channel of the transfected FRET sensor. 
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thought it would be valuable to generate both nuclear- localized and cytoplasmic Zn2+ sensors of 
the non-CFP/YFP variety.  To localize sensors to either the nucleus or cytosol a nuclear 
localization signal (NLS) or nuclear exclusion signal (NES) was incorporated into the pcDNA 3.1 
(+) mammalian expression vector upstream of the sensor.  Both signal sequences were verified 
by sequence analysis followed by the direct observation of localization in cells.  Figure 4.1a  
shows a schematic of the sensor construct illustrating the localization signals.  Figure 4.1b 
shows a representative FRET sensor localized to either the nucleus or the cytosol.  All sensors 
exhibited a similar localization pattern. 
 4.4.3 Characterization of sensors in HeLa Cells 
 There are many examples of genetically encoded biosensors exhibiting diminished 
responses in cells compared to in vitro (16), therefore we set out to screen all sensors in 
mammalian cells to verify functionality.  All six sensors described in Table 4.3 were transiently 
transfected into HeLa cells, expressed in either the nucleus or cytosol, and subjected to an in 
situ calibration to determine Rresting, RTPEN, and RZn.  This calibration involved treatment of cells 
with 150 µM TPEN to chelate Zn2+ and obtain the FRET ratio in the Zn2+-free state (RTPEN), 
followed by a washout and treatment with 10 µM digitonin to permeabilize the cell membrane 
and addition of 135 µM ZnCl2 to saturate the sensor and obtain the FRET ratio of the Zn
2+-
bound state (RZn).  Figure 4.5 shows that all nuclear-localized sensors responded to 
manipulation of cellular Zn2+, with the majority of sensors exhibiting an increase in the FRET 
ratio for RZn and a decrease for RTPEN.  ZapCmR1 was the only sensor that displayed an 
inverted response (RTPEN > RZn).  It is not uncommon for sensors to exhibit inverted FRET 
responses when the relative orientation of the FPs is altered (17), particularly when the linkers 
are different as they are in the Clover-mRuby2 construct.  Incorporation of mutations in the ZBD 
reverted the response to that of other sensors, and decreased the affinity for Zn2+ as observed 
by comparison of RTPEN and RZn with other sensors.  Figure 4.6 shows that all sensors localized 
tot the cytosol responded to manipulation of cellular Zn2+. 
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 The dynamic range of a sensor provides a measure of the sensitivity is defined as 
RZn/RTPEN.  Table 4.6 presents the dynamic range for each sensor, which varies from 1.1 to 1.2-
fold for most of sensors with the exception of ZapCmR1.1 and ZapCmR2 which exhibit a 1.4-1.5 
fold change.  Two additional important parameters are the resting FRET ratio and the Rmax – 
Rmin which help to define the signal-to-noise.  For example if the dynamic range is 1.1 and the 
resting ratio is 0.5, this means the FRET ratio only changes from 0.5 to 0.55, i.e. Rmax – Rmin is 
0.05; whereas if the resting ratio is 1.0, the same dynamic range would yield a FRET ratio 
change from 1 to 1.1 and hence an Rmax – Rmin of 0.1 and overall greater sensitivity.  From 
Table 4.6, ZapSM2, ZapSR2, ZapOC2, and ZapCmR1 exhibit comparable sensitivity, whereas 
ZapOK2 displays lower sensitivity.  Both ZapCmR1.1 and ZapCmR2 exhibit substantially 
greater sensitivity when compared to the other FRET sensors from Table 4.6. 
 The percent saturation is a measure of how much Zn2+ is bound to a sensor under 
resting conditions and provides a relative measure of Zn2+ levels in different locations. Table 4.6 
shows the resting percent saturation of each sensor in the nucleus and cytosol.  Interestingly, all 
six sensors reveal a higher saturation percentage in the nucleus than the cytosol, suggesting 
that nuclear Zn2+ is buffered at a higher concentration than the cytosol.  The final sensor, 
ZapOK2 demonstrated a similar resting percent saturation in both compartments, although as 
explained above, this sensor had the lowest sensitivity.  Both ZapCmR1.1 and ZapCmR2 
displayed low percent saturation compared to wild-type ZapCmR1, as expected due to the 
incorporation of mutations to weaken the Zn2+-affinity. 
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Figure 4.5. FRET Sensor calibration in the nucleus.  Representative calibrations of each 
sensor localized to the nucleus.  The background corrected FRET ratio (FRET Intensity ÷ Donor 
Intensity) is represented as a function of time.  Calibrations were performed by adding 150 µM 
TPEN to achieve RTPEN, followed by washing of residual TPEN and addition of 135 µM ZnCl2 
with 10 µM Digitonin to permeabilize the cell membrane and obtain RZn.  A) NLS-ZapSM2 FRET 
ratio increases slightly above resting suggesting that it is close to saturation at rest; B) NLS-
ZapSR2, FRET ratio goes above resting; C) NLS-ZapOC2 has a small decrease in FRET ratio 
after TPEN and a larger increase after treatment with Zn2+; D) NLS-ZapOK2 exhibits a small 
change in FRET ratio after TPEN and Zn2+; E) NLS-ZapCmR1 has an inverted response in 
which TPEN causes an increase in FRET ratio while Zn2+ with digitonin causes a decrease in 
the ratio; F) NLS-ZapCmR1.1 displays a decrease in the FRET ratio after TPEN and large 
increase with Zn2+ and digitonin; G) NLS-ZapCmR2 is similar to ZapCmR1.1.  Representative 
traces are mean ± s.e.m. (n = 4 cells).  Each experiment was repeated a minimum of three 
times. 
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Figure 4.6. FRET Sensor calibration in the cytosol.  Representative calibrations of each 
sensor localized to the cytosol. The background corrected FRET ratio (FRET Intensity ÷ Donor 
Intensity) is represented as a function of time.  Calibrations were performed by adding 150 µM 
TPEN to achieve RTPEN, followed by washing of residual TPEN and addition of 135 µM ZnCl2 
with 10 µM Digitonin to permeabilize the cell membrane and obtain RZn.  A) NES-ZapSM2, 
FRET ratio goes slightly above resting; B) NES-ZapSR2 has a similar response as observed in 
the nucleus, Figure 2B; C) NES-ZapOC2 demonstrates a small decrease after TPEN compared 
to the same sensor in the nucleus; D) NES-ZapOK2 is observed with small changes in FRET 
ratio after TPEN and Zn2+/digitonin; E) NES-ZapCmR1 has an inverted response in which TPEN 
causes an increase in FRET ratio while Zn2+ with digitonin causes a decrease in the ratio; F) 
NES-ZapCmR1.1 and G) NES-ZapCmR2 exhibit a small decrease with TPEN and a larger 
increase in FRET ratio after addition of Zn2+ and digitonin.  Representative traces are mean ± 
s.e.m. (n = 4 cells).  Each experiment was repeated a minimum of three times. 
 
 
 
 
 
 
 
 
 
  
 
129 
 
Table 4.6. Comparison of sensors with different fluorescent proteins 
Sensor Name In vivo Dynamic Range 
(Rmax/Rmin) (Mean±SEM) 
Percent Saturation at Rest [(R-
RTPEN)/(RZn-TPEN)x100% 
(Mean±SEM) 
Rrest Rmax-Rmin 
NLSZapSM2 1.14 ± 0.003 91% ± 3% 0.89 0.11 
NESZapSM2 1.13 ± 0.01 67 ± 5% 1.05 0.15 
NLSZapSR2 1.18 ± 0.004 48 ± 3% 0.55 0.1 
NESZapSR2 1.21 ± 0.01 38 ± 2% 0.52 0.1 
NLSZapOC2 1.11 ± 0.01 22 ± 2% 0.88 0.12 
NESZapOC2 1.13 ± 0.01 20 ± 2% 0.74 0.13 
NLSZapOK2 1.1 ± 0.01 32 ± 4% 0.93 0.06 
NESZapOK2 1.09 ± 0.004 35 ± 2% 1.09 0.08 
NLSZapCmR1 1.15 ± 0.01 92 ± 2 1.02 0.15 
NESZapCmR1 1.17 ± 0.04 88 ± 7 1.07 0.18 
NLSZapCmR1.1 1.44 ± 0.5 22 ± 6 1.22 0.4 
NESZapCmR1.1 1.52 ± 0.03 17 ± 1 1.43 0.6 
NLSZapCmR2 1.38 ± 0.02 24 ± 1 1.38 0.4 
NESZapCmR2 1.39 ± 0.02 17 ± 1 1.28 0.5 
*Each experiment was performed in triplicate and a minimum of 3-4 cells per field of view were observed. 
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 4.4.4 Zinc uptake into the cytosol and nucleus 
 Extracellular Zn2+ levels are typically in the 1-10 µM range (29-31), but a number of cells 
contain high levels of Zn2+ in vesicles and secrete Zn2+ in response to stimulation (32-35).  
Therefore, there are physiological situations in which extracellular Zn2+ is transiently elevated.  
We have demonstrated that elevation of extracellular Zn2+ results in uptake of Zn2+ into the 
cytosol, increasing the level of free Zn2+ from approximately 100 pM to 6 nM (15), but it is 
unclear whether an increase in cytosolic Zn2+ leads into an increase in nuclear Zn2+.  Therefore 
we set out to monitor Zn2+ uptake in both the cytosol and nucleus with the new sensors.  Sensor 
cDNA were transfected into each compartment and the FRET ratio was observed after the 
addition of 100 µM ZnCl2.  Figure 4.7 depicts representative traces of each sensor in the 
cytosol upon elevation of extracellular Zn26+, confirming with that the new sensors are sensitive 
enough for monitoring Zn2+ uptake.  Figure 4.8 demonstrates that all nuclear sensors exhibit an 
increase in the FRET ratio, indicating that nuclear Zn2+ also rises under this experimental 
paradigm.  Because ZapCmR1 was close to saturated under resting conditions, we did not use 
this sensor for uptake studies. 
 While the clover-mRuby2 sensors clearly represent superior green-red sensors, we 
wanted to test the limits of responsiveness of the low dynamic range sensors.  Therefore, we 
co-transfected NLS-ZapSM2, -ZapSR2, -ZapOC2, and -ZapOK2 sensors with a NES-ZapCY2 
to simultaneously monitor Zn2+ uptake into the nucleus and cytosol.  ZapCY2 was used in the 
cytosol due to its lower affinity (Kd' = 811 pM) for Zn
2+ compared to ZapCY1 which is saturated 
at rest due to its high affinity (Kd' = 2.53 pM) (15).  Figure 4.9 reveals that two sensors (NLS-
ZapSR2 and -ZapOC2) were sensitive enough to detect changes in nuclear Zn2+ when coupled 
with cytosolic ZapCY2.  Moreover, under this experimental paradigm, the cytosol and nucleus 
accumulated Zn2+ with comparable rates, indicating that in defining the rate of Zn2+ uptake from 
the extracellular environment, localizing sensors to the nucleus could serve as a proxy for  
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Figure 4.7. Zn2+ uptake into cytosol.  Sensors were localized to nucleus to monitor uptake of 
extracellular Zn2+.  A) NLS-ZapSM2, B) NLS-ZapSR2, C) NLS-ZapOC2, D) NLS-ZapCmR1.1, 
E) NLS-ZapCmR2.  Regions were imaged for approximately 300 seconds followed by the 
addition of 100 µM extracellular ZnCl2 at the time indicated.  Nuclear FRET ratios rose 
immediately after the addition of Zn2+.  The background corrected FRET ratio (FRET Intensity ÷ 
Donor Intensity) is represented as a function of time. Each experiment was repeated a minimum 
of three times with a minimum of 3-4 cells per field of view. 
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Figure 4.8. Zn2+ uptake into nucleus.  Sensors were localized to nucleus to monitor uptake of 
extracellular Zn2+.  A) NLS-ZapSM2, B) NLS-ZapSR2, C) NLS-ZapOC2, D) NLS-ZapCmR1.1, 
E) NLS-ZapCmR2.  Regions were imaged for approximately 300 seconds followed by the 
addition of 100 µM extracellular ZnCl2 at the time indicated.  Nuclear FRET ratios rose 
immediately after the addition of Zn2+.  The background corrected FRET ratio (FRET Intensity ÷ 
Donor Intensity) is represented as a function of time. Each experiment was repeated a minimum 
of three times with a minimum of 3-4 cells per field of view. 
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Figure 4.9. Simultaneous monitoring of cytosolic and nuclear Zn2+ uptake .  (A) 
Simultaneous imaging of NLS-ZapSR2 and NES-ZapCY2 in the same cell. (B) Simultaneous 
imaging of NLS-ZapOC2 and NES-ZapCY2 in the same cell.  In both experiments 100 µM ZnCl2 
was added at the time indicated.  The rate of increase in the FRET ratio is essentially the same 
in both locations, suggesting similar rates for nuclear and cytosolic uptake.  C) Left panel 
(cytosol) is NES-ZapCY2 and circles represent ROI followed throughout experiment, middle 
panel represents NLS-ZapSR2, circles represent ROI (NLS-ZapOC2 not shown), and right 
panel represents NLS-ZapSR2 and NES-ZapCY2 merged.  Images were bleedthrough 
corrected.  Experiments were repeated at least five times with a minimum of 1-2 cells per 
experiment.  Scale bar = 20 µm. 
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monitoring the rate of change of cytosolic Zn2+.  NLS-ZapSR2 exhibited the largest FRET ratio 
change compared to NLS-ZapOC2, making it the preferable choice of low sensitivity sensors.  
Experiments in which NLS-ZapSM2 and NLS-ZapOK2 were used with NES-ZapCY2, only the 
cytosolic sensor exhibited an increase in FRET upon Zn2+ (Data Not Shown), suggesting these 
sensors had limited sensitivity to monitor physiological fluxes of cellular Zn2+. 
 4.4.5  Simultaneous monitoring of nuclear and organelle Zn2+ uptake 
 Previous studies in our lab have demonstrated that intracellular organelles such the ER, 
Golgi, and mitochondria can accumulate Zn2+ when cytosolic Zn2+ levels become elevated, 
demonstrating these compartments play an important role in cytosolic clearance and 
maintenance of homeostasis (15, 36).  However for these prior experiments accumulation of 
Zn2+ in the cytosol and intracellular organelles was measured in separate experiments making it 
impossible to directly compare the relative rate of uptake in individual cells. To observe Zn2+ 
uptake into the nucleus we continued to use NLS-ZapSR2 because it yielded the most robust 
signal compared to the other sensors and ZapCY1 was targeted to individual organelles.  
Figure 4.10a,c,e depicts representative images showing sensor localization.  As observed in 
Figure 4.10b,d,f, addition of 100 µM ZnCl2 to the extracellular milieu, gave rise to an immediate 
increase in nuclear Zn2+, whereas organelle Zn2+ (ER, Golgi, and mitochondria,) increases 
approximately 600-700 seconds later, and only after the nuclear Zn2+ begins to decline. 
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Figure 4.10. Simultaneous monitoring of Zn2+ uptake into the nucleus and either the ER, 
Golgi apparatus, or mitochondria.  Representative images (FRET channel) and FRET ratio 
traces of Zn2+ uptake into the nucleus, ER, Golgi, or mitochondria are presented.  A) Image of 
nuclear and ER FRET sensor, left panel illustrates NLS-ZapSR2, middle panel ER-ZapCY1 and 
right panel is a pseudo-color merged image of NLS-ZapSR2 and ER-ZapCY1.  B) Image of 
nuclear and ER FRET sensor, left panel illustrates NLS-ZapSR2, middle panel Golgi-ZapCY1 
and right panel is a pseudo- color merged image of NLS-ZapSR2 and Golgi-ZapCY1. C) Image 
of nuclear and mitochondrial FRET sensor, left panel illustrates NLS-ZapCmR2, middle panel 
mitochondria-ZapCY1 and right panel is a pseudo- color merged image of NLS-ZapCmR2 and 
mitochondria-ZapCY1. D-F) FRET ratio traces of NLS-ZapSR2 or NLS-ZapCmR2 with ER-, 
Golgi-, and mitochondrial-ZapCY1 upon addition of 100 µM extracellular ZnCl2 at the time 
indicated.  The nuclear FRET ratio rises more rapidly than organelle FRET ratio.  The organelle 
FRET ratio begins to increase approximately 600 seconds post-Zn2+.  Experiments were 
repeated at least five times with a minimum of 1-2 cells per experiment.  All images were 
bleedthrough corrected.  Scale bar = 20 µm. 
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4.5 Discussion  
 Here we report the first alternatively colored Zn2+ sensors using FPs constructed from 
green, orange, and red FPs, that can be used simultaneously with a CFP-YFP sensor as the 
first step toward monitoring Zn2+ in multiple subcellular locations.  Given the evidence that 
changes in cellular Zn2+ have been linked with changes in other ions such as Ca2+ (15, 37) and 
signaling pathways such as the MAPK pathway (38) and apoptotic cascades (39, 40) a broad 
palette of Zn2+ sensors that permits simultaneous monitoring of multiple events would be useful 
tools to provide mechanistic insight into these connections. 
 Sensors were targeted to both the cytosol and nucleus and intriguingly, 6 of the 7 
sensors registered a higher fractional saturation in the nucleus compared to the cytosol, 
suggesting the possibility that nuclear Zn2+ may be buffered at a higher concentration than 
cytosolic Zn2+.  Although there are currently no estimates of nuclear Zn2+ levels, given the large 
number of transcription factors that bind Zn2+ (41) it seems reasonable to speculate the nuclear 
buffering system may differ from that in the cytosol. 
 The development of multi-color FRET sensors for Zn2+ allowed us to monitor Zn2+ 
simultaneously in the nucleus and other organelles, such as the ER, Golgi, or mitochondria.  For 
these experiments we measured Zn2+ uptake or sequestration following acute elevation of 
extracellular Zn2+.  Extracellular Zn2+ levels are typically in the range of 1 to 10 µM.  However 
there are a number of cell types (hippocampal neurons, prostate cells, and pancreatic cells) that 
are known to secrete Zn2+.  Although the amount of Zn2+ these cells secrete has not been 
rigorously quantified, estimates range from 1 µM to 2 mM (32-35).  Therefore we believe the 
acute elevation of extracellular Zn2+ represents a physiologically relevant stimulus similar to Zn2+ 
secretion.  Here we demonstrate that elevation of extracellular Zn2+ leads to immediate uptake 
of Zn2+ into the nucleus and much slower sequestration of Zn2+ into organelles after a lag time of 
~ 600 seconds.  The reason for organelle sequestration is unclear but it may represent a 
 137 
 
detoxification mechanism, ensuring that cytosolic levels of Zn2+ don't get too high.  The 
mechanism of sequestration and the reason for the delay are unclear.  There are 24 mammalian 
Zn-transporters with varied subcellular distribution and it is possible that specific transporters 
are activated for Zn2+ transport into organelles (42).  We believe these new tools (i.e. sensors 
targeted to multiple locations to simultaneously monitor Zn2+ flux) will allow us to dissect these 
fundamental questions about Zn2+ homeostasis. 
 In contrast to the robust signal that is observed using CFP and YFP as a FRET pair, 
alternate color FRET pairs often suffer from greatly reduced dynamic ranges.  Additionally, 
because of the lower quantum yields of most red FPs compared to appropriate donor FPs and 
the relatively poor sensitized emission, FRET sensors with a red FP as the acceptor typically 
yield a resting FRET ratio less than 1 and a reduced ∆R, thus limiting their sensitivity.  Not 
surprisingly the majority of sensors reported here exhibit modest FRET ratio changes.  Of the 5 
different FRET pairs explored, Clover-mRuby2 based sensors yielded the greatest sensitivity 
with a dynamic range of 1.4-1.5 and ∆R of 0.4-0.6.  The other FRET sensors exhibited a lower 
∆R making them less robust for monitoring cellular Zn2+ fluxes, although many were still 
sensitive enough to permit measurement of subtle changes in cellular Zn2+ levels.  Still, 
ZapCmR1.1 and ZapCmR2 are clearly superior and even exhibit a slightly better dynamic range 
than their CFP-YFP counterpart, ZapCY2 (15). 
 In conclusion, we have established new genetically encoded Zn2+ sensors employing 
FRET pairs that are complementary to the traditional CFP-YFP pair that can help define Zn2+ 
dynamics in different compartments simultaneously.  A limitation of some of these alternately 
colored biosensors is that their dynamic range is reduced compared to their CFP-YFP 
counterparts (1.1-1.2 versus 1.3-1.4).  However, we did identify superior sensors based on the 
new FRET pair Clover and mRuby2, which have higher dynamic ranges than their CFP-YFP 
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counterparts.  These green-red sensors should also be useful for monitoring Zn2+ levels 
alongside other signaling agents such as Ca2+ and therefore have the potential to be 
instrumental in dissecting crosstalk between these two ions.  Given the lower pKa values of 
green and red FPs compared to YFP, we anticipate these sensors will be more resistant to 
quenching at lower pHs and hence may be particularly useful for quantifying Zn2+ when targeted 
to acidic compartments. 
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5.1 Abstract 
 Zinc (Zn2+) is important in many biological processes and it is an essential component 
throughout the cell.  As evident from previous chapters we have observed Zn2+ pools in the ER, 
mitochondria, cytosol, and nucleus of our prostate cell line models with genetically encoded 
fluorescent sensors localized to each compartment.  While we have almost obtained a full map 
of labile Zn2+ of prostate cells, we are lacking quantification of Zn2+ in the Golgi and vesicles.  
Therefore, we set out to develop a FRET-based sensor genetically targeted to vesicles.  Initially, 
mCherry was fused to the C-terminus of Vesicle-Associated Membrane Protein 2 (VAMP2) , a 
single transmembrane domain protein,  and transfected into cells as a positive control for 
vesicular localization.  To observe if VAMP2-mCherry localized to Zn2+ containing vesicles, cells 
were transfected with VAMP2-mCherry and stained with FluoZin3-AM, a commonly used small 
molecule dye for visualizing vesicular Zn2+.   Subsequently, VAMP2 was fused to the N-terminus 
of the green-red sensor developed in Chapter IV, resulting in the first functional, vesicle-
targeted, ratiometric Zn2+ sensor.   
5.2 Introduction 
 Zinc is the second most abundant transition metal and is an essential cofactor for 
numerous proteins and enzymes such as acetylcholinesterase (1), alcohol dehydrogenase, 
DNA and RNA polymerases, Nerve Growth Factor (NGF) (2), and finally transcription factors 
such as Zif268 (3) and Metal Transcription Factor-1 (MTF1) (4).  The total Zn2+ in mammalian 
cells is estimated to be 0.1 - 0.5 mM (5, 6).  Most of this Zn2+ is bound by proteins, enzymes, 
and cellular ligands, however free Zn2+ has been identified in vesicles in brain (7, 8), prostate 
(8), and pancreatic islets cells (9).  While we have developed tools to monitor Zn2+ in many 
different compartments of the cell, there are still no robust ratiometric sensors for defining the 
amount of free Zn2+ in vesicular compartments. 
 Zinc is known to be concentrated into secretory vesicles and this vesicular Zn2+ plays 
biological functions in the cells.  In the brain, vesicular Zn2+ has been shown to regulate synaptic 
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transmission.  Zinc is stored in vesicles that are assembled in the Golgi along with glutamate 
and are released upon electrical stimulation in glutamatergic neurons (10).  Mice that cannot 
store Zn2+ in vesicles develop amyloid pathology (11). In addition, pancreatic β -islet cells contain 
vesicular Zn2+ which helps to stabilize insulin within vesicles (12, 13).  It is evident that Zn2+ is a 
major signaling agent and may act in some major signaling pathways in the brain and pancreas 
(14, 15).  In order to more thoroughly investigate vesicular Zn2+ we need to develop tools that 
are easily targeted to vesicles, unaffected by pH, and sensitive to Zn2+. 
 Because of the importance of Zn2+ in vesicles we need to develop new tools to monitor 
and quantify the level of free Zn2+ in this specific compartment.  Currently the only way to 
monitor vesicular Zn2+ in cells is to use an intensiometric small molecule dye and the most 
commonly used dye is the commercially available FluoZin3-AM (acetoxymethyl (AM) ester) (16).  
This dye is an intensity based dye, meaning the more Zn2+ it binds the higher the fluorescent 
output.  A problem with this is that the fluorescence output is also determined by the amount of 
FluoZin3 in the cell.  Additionally, the dye does not explicitly target vesicles, but rather is present 
in both the cytosol and vesicles, making it difficult to separate contributions from each of these 
locations.  For this reason we need genetically encoded FRET sensors that are ratiometric and 
are specifically targeted to vesicles.   
The vast majority of FRET sensors are comprised of CFP-YFP, as noted in a recent 
publication (17).  A sensor comprised of a CFP-YFP would not be useful in vesicles because the 
pKa of the chromophore of YFP is about 6.0 (18, 19) and hence fluorescence would be 
quenched in vesicles where the pH between 4.5 - 6 (20, 21).  Because of this we need to swap 
the CFP-YFP for a green-red sensor, because green and red fluorescent proteins have lower 
pKa's and would potentially respond in an acidic environment such as vesicles.   
In Chapter IV, we describe a new FRET sensor based on Clover and mRuby2 (22) 
fluorescent proteins with a Zn2+ finger nested between them.  To determine if we can monitor 
Zn2+ in vesicles we used the Vesicle-Associated Membrane Protein 2 (VAMP2) which is a single 
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transmembrane domain.  This single transmembrane domain protein is useful because it is 
attached to early and late endosomes (23) and has its C-terminus localized in the luminal side 
of the vesicle for easily attaching a FRET sensor.  In preliminary data we have targeted VAMP2-
ZapCmR1.1 sensor to vesicles and have observed robust localization to vesicles in HeLa cell 
line.   
5.3 Experimental Methods 
VAMP2 and FRET Sensor Cloning.  A schematic of the general sensor construct is presented 
in Figure 5.1 and VAMP2 targeting domain in Figure 5.2.  VAMP2 was obtained by polymerase 
chain reaction (PCR) and cloned into a mammalian expression vector pcDNA3.1 (+) (Life 
Technologies) between HindIII and BamHI restriction sites and verified by sequence analysis.  
To create VAMP2-mCherry, the mCherry fluorescent protein DNA sequence was amplified by 
PCR and subcloned into pcDNA3.1 (+) using BamHI and EcoRI restriction sites and verified by 
sequence analysis.  VAMP2-mCherry was created to observe localization of a VAMP2-targeted 
construct alongside FluoZin3 to determine if indeed VAMP2 targeted Zn2+ containing vesicles.  
To generate a Zn2+ sensor targeted to vesicles, ZapCmR1.1 was removed from pET302/NT-His 
(Life Technologies) using BamHI and EcoRI restriction sites and subcloned into pcDNA3.1 (+) 
VAMP2 and verified by sequence analysis. 
Cell Culture and Microscopy.  HeLa cells were grown in Dulbecco's Modified Eagle's Medium 
(DMEM) (Life Technologies) supplemented with 10% (v/v) fetal bovine serum (Atlanta 
Biologicals), 100 U/mL penicillin, and 100 µg/mL streptomycin.  Cells were incubated at 37°C in 
5% CO2, changing the media every 3 days.  Once cells were approximately 80-90% confluent 
they were split and seeded onto 3.5 cm imaging dishes until they were approximately 40-50% 
confluent.  At this point 1 µg of VAMP2-mCherry or VAMP2-ZapCmR1.1 was transiently 
transfected using TransIT®-LT1 (Mirus) as specified by manufacturer instructions. 
 Forty-eight hours after transfection, cells were imaged using phosphate, calcium, and 
magnesium free HEPES-buffered Hanks' balanced salt (HHBSS) media (5.36 mM KCl, 137 mM  
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Figure 5.1.  Schematic diagram of FRET Sensor.  The sensor is composed a Clover 
Fluorescent Protein, mRuby2 Fluorescent Protein, and a Zn2+ binding domain derived from the 
first two zinc fingers of Zap1.  The Zn2+ binding domain is relatively unstructured in the absence 
of Zn2+ and undergoes a conformational change upon Zn2+ binding leading to an increase in 
FRET from the donor Clover to the acceptor mRuby2. 
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Figure 5.2.  Schematic diagram Vesicle-Associated Membrane Protein 2 (VAMP2) with 
ZapCmR1.1 FRET sensor.  VAMP2 is a single transmembrane protein that target vesicles and 
is a part of the SNARE machinery.  ZapCmR1.1 was cloned onto the C-terminus of VAMP2 so 
that its spatial location resided in the luminal space of the vesicle to monitor Zn2+ content. 
 
 
 
 
 
 
 
Vesicle 
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NaCl, 16.65 mM D-Glucose, and 30 mM HEPES) pH 7.4.  This buffer is made in our laboratory 
because phosphates are known to precipitate Zn2+.  Buffer was generated with Chelex-100-
treated water (Sigma Aldrich).  Cell imaging was performed on a Zeiss Axiovert 200 M 
microscope with a Cascade 512B CCD camera (Roper Scientific) and Xenon arc lamp (XBO75) 
using MetaFluor software (Universal Imaging) to operate the system.  The following settings 
were used: exposure time 600 msec, 20-30 second acquisition rate, 1.3NA 40x oil immersion 
objective, and excitation light was attenuated with a 5% neutral density filter for VAMP2- 
mCherry and VAMP2-ZapCmR1.1.  mCherry fluorescent protein was excited with a 577/20 
(nm/bandwidth) excitation filter, dichroic 595 nm, and 630/60  (nm/bandwidth) emission filter.  
FluoZin3 was excited with a 495/10 (nm/bandwidth) excitation filter, dichroic 515 nm, and 
535/20  (nm/bandwidth) emission filter.  Clover fluorescent protein was excited with a 480/20 
(nm/bandwidth) excitation filter, dichroic 495 nm, and 510/20 (nm/bandwidth) emission filter.  
mRuby2 fluorescent protein was excited with a 540/25 (nm/bandwidth) excitation filter, dichroic 
565 nm, and 595/20  (nm/bandwidth) emission filter.  ZapCmR1.1 FRET sensor was excited 
with a 480/20 (nm/bandwidth) excitation filter, dichroic 565 nm, and 595/20 (nm/bandwidth) 
emission filter. 
 In addition to using a Zeiss Axiovert 200M microscope, we used a Nikon Ti-E 
microscope with a Perfect Focus System (PFS) for maintenance of sample focus, Differential 
Interference Contrast (DIC), Motorized XY stage with piezo Z-Drive insert for rapid 
multidimensional (XYZ) imaging and photomultiplier tubes (PMTs) to collect images.  Images 
were analyzed using Nikon Elements software.  A 100X objective was used with NA 1.4, 488 
nm (FluoZin3), and 561 nm (mCherry) excitation laser light was used.  A 525/50 (nm/bandwidth) 
and 650/50 (nm/bandwidth) confocal emission filters were used for FluoZin3 and mCherry, 
respectively. 
Live Cell Imaging Experiments.  To observe if VAMP2 localized to Zn2+ containing vesicles, 
VAMP2-mCherry transfected cultured cells were incubated with 2 µM FluoZin3 (Kd' = 15 nM; 
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Life Technologies) and 5 µL 20% Pluronic F-127 for 1 hour in phosphate free HHBSS buffer at 
room temperature in a dark place.  Following incubation, the cells were washed with HHBSS 
two times to remove extracellular excess dye and 1 mL of HHBSS buffered was left with cells 
and placed in a dark environment to allow time for cleavage of the AM ester.  Vesicles were 
followed for approximately 40 minutes with 30 second acquisition rate of FluoZin3 and mCherry 
channels. 
 To characterize VAMP2-ZapCmR1.1 in cells, a region of interest (ROI) was placed on an 
individual vesicle and on an untransfected cell or a region in the field of view with no cells as a 
measure of the background fluorescence.  The FRET channel is defined as the emission 
intensity in the acceptor FP channel, upon excitation of the donor.  The FRET ratio is defined as 
the background corrected intensity in the FRET channel divided by the background corrected 
intensity in the donor channel, i.e. (IFRET - IFRETbackground)/(IDonor - Idonorbackground).  For imaging 
experiments, DMEM media was removed and cells were washed twice with HHBSS buffer 
followed by the addition of 1 mL HHBSS.  ROIs were followed for 300 seconds to establish a 
resting R followed by the addition of 150 µM TPEN (N,N,N',N'-tetrakis-(2-pyridylmethyl)-
ethylenediamine) to chelate Zn2+ and obtain the FRET ratio of the unbound sensor (RTPEN).  
Once RTPEN was established, cells were washed 3-times with the HHBSS solution to remove 
residual TPEN followed by addition of 1 mL of fresh HHBSS.  Subsequently, 100 µM ZnCl2 and 
2 µM pyrithione was added to saturate the sensor and establish the FRET ratio of the Zn2+ 
bound sensor (RZn).  Data were collected at 20-30 sec acquisition rate.  The dynamic range of a 
sensor was defined as the maximum FRET ratio divided by the minimum FRET ratio (Rmax/Rmin), 
and the percent saturation was calculated according to [(|R-RTPEN|)/(|RZn-RTPEN|)]*100%. 
5.4 Results 
 5.4.1 VAMP2 and FluoZin3-AM Colocalization.   
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 VAMP2 is a single pass transmembrane protein that is part of the ubiquitous SNARE 
complex involved in vesicle fusion.  To assess whether VAMP2 colocalized with Zn2+-containing 
vesicles, we created VAMP2-mCherry which can be imaged simultaneously with the green 
FluoZin3 small molecule dye.  Although FluoZin3 targeting is inexact and in some cases 
ambiguous, it represents the current best way to visualize vesicular Zn2+.  As shown in Figure 
5.3a VAMP2-mCherry robustly localizes to vesicles in HeLa cells.  In some cells, there is co-
localization with FluoZin3 (denoted by the arrow in Figure 5.3a).  However, the staining of 
vesicles by FluoZin3 was highly variable and vesicular localization of the dye was difficult to 
detect in many cells.  For example,  Figure 5.3b shows that HeLa cells stained with FluoZin3 
exhibit poor illumination of vesicles, while VAMP2-mCherry robustly localizes to numerous 
vesicles throughout the cell.  These results suggest that VAMP2 robustly targets vesicle 
populations in cells and looks to be a good targeting motif for a Zn2+ sensor. 
 5.4.2 VAMP2-ZapCmR1.1 in vivo Calibration 
 VAMP2 is localized to early and late endosomes (23) as well as localizing to exocytic 
vesicles that are sorted in the trans-Golgi network (TGN) (24).   Figure 5.4a depicts HeLa cells 
transfected with the VAMP2-ZapCmR1.1 sensor and demonstrates localization of the sensor to 
puncta, consistent with localization to vesicles.  The bright fluorescence intensity of the sensor 
indicates that the chromophore fluorescence is not quenched by the low pH of vesicles.  To 
determine if the sensor responds to perturbations of cellular Zn2+ an in situ calibration was 
performed to measure the Rresting, RTPEN, and RZn.  This calibration involved treatment of cells 
with 150 µM TPEN to chelate Zn2+ and obtain the FRET ratio in the Zn2+-free state (RTPEN), 
followed by a washout and treatment with 2 µM pyrithione to permeabilize all cell membranes 
and addition of 100 µM ZnCl2 to saturate the sensor and obtain the FRET ratio of the Zn
2+-
bound state (RZn).  Figure 5.4b shows two traces from two independent vesicles that VAMP2-
ZapCmR1.1 responded to manipulation of cellular Zn2+ exhibiting an increase in the FRET ratio 
for RZn and a decrease for RTPEN. 
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Figure 5.3.  Fluorescence images of FluoZin3 and VAMP2-mCherry.  A) Left image 
represents FluoZin3 stain, middle image is VAMP2-mCherry, and right image represents co-
localization of FluoZin3 and VAMP2-mCherry.  Arrow points to a vesicle containing FluoZin3 
and VAMP2-mCherry.  B) Left image demonstrates poor vesicular staining by FluoZin3 and right 
image demonstrates robust vesicular localization of VAMP2-mCherry.  Scale bar = 20 µm. 
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Figure 5.4.  Calibration of VAMP2-ZapCmR1.1 in HeLa cells.  A) HeLa cell line transfected 
with VAMP2-ZapCmR1.1 localized to vesicles.  B) Two region of interest of vesicle Zn2+ 
measured using VAMP2-ZapCmR1.1.  To calibrate the sensor, a region of interest is followed 
for 300 seconds followed by the addition of 150 µM TPEN to chelate Zn2+.  Once the minimum 
FRET ratio is established TPEN is washed out and subsequently 100 µM Zn2+ with 2 µM 
Pyrithione is added to saturate the sensor and obtain a maximum FRET ratio.  Scale Bar = 20 
µm. 
 
 
 
 
 
 
 The dynamic range of a sensor provides a measure of the sensitivity is defined as 
RZn/RTPEN.  VAMP2-ZapCmR1.1 exhibited a dynamic range of about 1.6 fold, similar to some of 
our CFP-YFP sensors (25).  The percent saturation is a measure of how much Zn2+ is bound to 
a sensor under resting conditions and provides a relative measure of Zn2+ levels.  ZapCmR1.1 
154 
 
in cells exhibited a percent saturation of about 30% in the vesicles observed. Although we have 
not performed in vitro characterization to determine the Kd' of the sensor we estimate to be in 
the high pM range because the percent saturation is similar to that of our CFP-YFP sensor (25).  
Although this is an estimate based on calibration of the sensor in the cytoplasm to the Kd’ is 
likely to change as a function of pH.  In previous studies that determined the Kd' under different 
pHs the binding affinity the Zn2+ binding domain weakens at low pH (26, 27).  Our preliminary 
data of VAMP2-ZapCmR1.1 sensor demonstrate that the sensor has a good signal-to-noise 
ratio, responds to our calibration, and its fluorescence does not seem to be affected by the low 
pH of the vesicle.  In previous study that used a genetically encoded FRET sensor fused to 
VAMP2 to look at Zn2+ in vesicles did not show any response (28).  A possible explanation could 
be that under acidic conditions the yellow FP quenched therefore no FRET ratio change was 
observed upon in vivo calibration or the binding domain was not sensitive to the amount of free 
Zn2+ in the vesicle.  We believe that this sensor represents an important landmark in being able 
to quantify Zn2+ in an acidic compartment as well as use it with other CFP-YFP sensors and be 
able to dissect Zn2+ signaling in vesicles. 
5.5 Discussion 
  While there is a growing repertoire of tools to monitor free Zn2+ in different cellular 
locations, there are still no ratiometric sensors, explicitly targeted to vesicles to quantify the 
amount of Zn2+ present in vesicles.  Yet growing evidence suggests that not only do vesicles 
represent one of the major storehouses of Zn2+ in cells, but also that vesicular Zn2+ plays 
important roles in cellular processes.  For example in the brain the absence of vesicular zinc 
has profound implications for neurotransmission and cortical plasticity (29).  In addition, in the 
pancreas, dysruption of vesicular Zn2+ is known to cause type 2 diabetes (30).  Although there 
exists a pool of Zn2+ in prostate cells do date nothing is known about it or if it implicated in 
disease progression.  In this work we created the first functional, ratiometric sensor genetically 
targeted to vesicles.  ZapCmR1.1 was tagged using VAMP2, resulting in robust localization to 
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vesicles in HeLa cells.  Our preliminary data suggest the vesicular localized sensor is 
fluorescent and response to perturbations of cellular Zn2+. 
 Until the development of our sensor, the most widely available probe to visualize 
vesicular Zn2+ was FluoZin3.  This small molecule probe lacks a specific targeting signal, and 
therefore while it typically highlights pools of vesicular Zn2+, staining is highly variable and 
results in illumination of both vesicles and the cytosol.  Such heterogeneity makes it difficult to 
track the vesicular pool.  Even so, this dye has been widely used in hippocampal neuron and 
pancreatic β -cells.  In hippocampal neurons it has been used to detect the release of Zn2+ from 
synaptic vesicles (31, 32) which is estimated to be approximately 100 µM (33).  Another study 
done on hippocampal vesicles observed Zn2+ to be around 1-10 µM (34).  These previous 
studies demonstrate the variability in trying to quantify vesicular Zn2+ in neurons using a small 
molecule fluorescent dye.  In addition to neurons, FluoZin3 has been used in pancreatic β -cells 
to monitor Zn2+ secretion from vesicles.  Gee and coworkers (35) found that vesicular Zn2+ in 
pancreatic β -cells is estimated to be 600 nM.  In addition to the challenges mentioned above 
with respect to variability in dye localization, an additional concern is that FluoZin3 was derived 
from a Ca2+ dyes and is still sensitive to this divalent ion (36).  Another problem, particularly with 
respect to quantification, is that the intracellular concentration of FluoZin3 can reach hundreds 
of micromolar, thus overwhelming the Zn2+ buffering capacity of the cell and leading to 
perturbations of cellular Zn2+ levels.   
 The development of VAMP2-ZapCmR1.1 FRET sensor will provide insight into the pool 
of Zn2+ in vesicles and how it differs from cell to cell.  In order to continue investigating and 
quantifying this Zn2+ we need to perform extensive in vitro characterization of this sensor.  
ZapCmR1.1 protein needs to be purified to determine the disassociation constant as a function 
of pH.  This will allow us to quantify free Zn2+ in vesicles.  Once this occurs we can move to cells 
and determine the pool of Zn2+ in vesicles in a number of cells with the ultimate goal in 
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identifying the underlying causes of disease that may be due to dysregulation of this metal in 
vesicles. 
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6.1 Zinc Dysregulation 
 Throughout this thesis I have detailed the importance of Zn2+ in cells and how proteins 
such as transporters regulate this metal.  I have focused on prostate cancer and found that 
prostate cancer cell lines are characterized by substantial dysregulation of cellular Zn2+.  This 
includes depletion of total Zn2+,  redistribution of free Zn2+ amongst intracellular stores, as well 
as alterations in the expression and regulation of Zn2+ transporters. 
 This has been a major landmark for us as I have developed the most comprehensive 
picture to date of the distribution of free Zn2+ among intracellular organelles and how this 
distribution may be altered by disease.  But I still need to perform more work in these cell lines.  
During our experiments I tried to quantify the free Zn2+ in the Golgi apparatus but our sensor 
appears to be fully saturated under resting conditions, suggesting that there are significantly 
higher levels of Zn2+ in the Golgi of prostate cells than in the model HeLa cell line used to 
validate the Golgi sensor.  The fact that the sensor is saturated precludes us from being able to 
quantify Zn2+ in the Golgi with this sensor.  It also suggests that prostate cells are fundamentally 
different from HeLa cells in that the Golgi may represent a major Zn2+ store.  As a first step 
toward addressing this issue, I cloned in the lower affinity ZapCY2 (1) into the Golgi construct.  
However, the current Golgi-targeting sequence doesn’t yield robust Golgi localization of ZapCY2 
in prostate cell lines.  Instead, typical observations reveal the sensor is primarily mislocalized to 
the ER.  Therefore our next steps are to try using a different Golgi targeting signal sequence, 
change the fluorescent proteins to variants that don’t dimerize in oxidizing compartments such 
as the secretory pathway (oxCerulean and oxVenus), and to test other low affinity Zn2+ binding 
motifs (it is surprising that ZapCY1 targets better than ZapCY2).  Once I obtain a sensor with 
robust localization, the sensor will be calibrated in the Golgi using methodology previously 
established in our lab.  Quantifying the free Zn2+ content in the Golgi of RWPE1 normal cell line 
and all three prostate cancer cell will be exciting and an important piece of the puzzle of how 
Zn2+ is dysregulated in prostate cancer.  In mice, Golgi Zn2+ has been implicated in prostate 
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cancer disease progression due a null mutation in the ZnT7 transporter which is  responsible for 
the accumulation of Zn2+ in this compartment (2).  In addition to quantifying the free Zn2+ in the 
Golgi it will interesting to sequence the ZnT7 Zn2+ transporter of all four cell line to determine if 
there are any differences. 
 Another key compartment is to profile whether there are any changes in vesicular Zn2+ in 
these prostate cells.  As mentioned in Chapter V, as part of this thesis work I developed the first 
functional ratiometric sensor explicitly targeted to vesicular compartments.  Before using this 
sensor to quantify vesicular Zn2+, the sensor itself needs to be better characterized.  In 
particular, future experiments will be necessary to determine the disassociation constant of the 
sensor as a function of pH, and ideally I would like to determine the dissociation constant in situ 
as well.  Once this characterization occurs I can move into cells and quantify the free Zn2+ in 
vesicles of the normal and cancerous prostate cell lines.   
   Another future direction is to determine how Zn2+ dyshomeostasis influences 
cellular functions.  One of the cellular functions that I hypothesize might be affected is the rate of 
apoptosis.  It has been shown that too much or little Zn2+ causes the cell to undergo apoptosis 
and that the intracellular pool of chelatable Zn2+ plays a critical role in this event as well (3-6).  
Elevated Zn2+ in the cytosol has been shown to inhibit caspases (7), thus inhibiting the apoptotic 
pathway.  To test whether the elevated cysotolic Zn2+ observed in the prostate cells makes 
these cells less sensitive to apoptotic stimuli, I will measure the proportion of cells undergoing 
apoptosis using a FACS-based assay under non-stimulated and stimulated conditions. If I 
observe a difference, I will test whether a low dose of a Zn2+-chelator alters the propensity of the 
cells to undergo apoptosis.  The Zn2+ chelator was characterized in a previous study in our 
laboratory by Dr. Yan Qin and she found that PAC-1 and S-PAC-1 chelated low levels of Zn2+ 
and activated procaspase-3 activity to induce apoptosis (8).   
6.2 Zinc Transporter Expression 
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 To begin to address why Zn2+ homeostasis is altered in prostate cancer cells, I 
measured the levels of key Zn2+ regulatory proteins, the ZIP transporters which control Zn2+ 
entry into the cytosol from the extracellular space or from intracellular organelles, and the ZnT 
transporters which control Zn2+ efflux from the cytosol, either across the plasma membrane or 
across the membranes of intracellular organelles.  Our results suggest that the mRNA and 
protein levels are often differentially regulated (i.e. elevated mRNA but decreased protein levels 
in a given cell line), indicating the importance of measuring both when building a map of the 
dysregulation of transporters associated with disease.  I observed, more often than not, that the 
mRNA expression did not correlate with the protein expression and our results have barely 
scratched the surface on Zn2+ dysregulation.  In order to better understand how (and whether) 
free Zn2+ levels are regulated by transporters, I need to quantify all 24 known transporters as 
well as the most common isoforms of the primary Zn2+ buffer, metallothionein. 
 To rigorously assess whether transporter expression indeed controls the observed Zn2+ 
levels requires manipulation of transporter expression levels and measurement of the resulting 
free Zn2+ in compartments across the cell because changes of Zn2+ in one compartment could 
lead to compensatory changes in other compartments  For example, I could partially knock 
down ZnT1 in prostate cancer cell lines and measure whether the levels of Zn2+ in the cytosol 
increase in prostate cancer cell lines by ICP-MS (total Zn2+) or using FRET-based sensors (free 
Zn2+).  These experiments will map the expression of all 24 Zn2+ transporters in normal 
compared to cancerous cell lines to ascertain if there are systematic differences which are 
responsible for the low levels of Zn2+ in prostate cancer cells. 
6.3 Conclusion 
 Prostate cancer will affect 1 in 6 men in our lifetime (9).  At this time the prognostic tools 
that physicians use are flawed.  One key component that a physician looks at during a regular 
examination is prostate specific antigen, but it is known to become elevated if the prostate is 
inflamed.  This gives false-positive results which lead to invasive and painful biopsies.  Over the 
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last decade researchers have looked at Zn2+ dysregulation in prostate cancer and have found in 
both cell lines and tissue biopsies that Zn2+ levels correlate with malignancy.  However, we have 
very little understanding of how and why Zn2+ is altered in prostate cancer.  If the changes in 
Zn2+ homeostasis can be precisely defined and if we determine that specific signatures of 
dysregulation (decreased total Zn2+, altered transporter expression, etc) give rise to and 
precede the onset of malignancy and metastasis, then Zn2+ dysregulation could potentially be 
used as a diagnostic biomarker of disease.  While we are still a long way off from establishing 
this, this thesis represents the first step to define the full extent of Zn2+ regulation at the cellular 
level. 
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